US20230390387A1 - Methods for making mixed allergen compositions - Google Patents
Methods for making mixed allergen compositions Download PDFInfo
- Publication number
- US20230390387A1 US20230390387A1 US18/232,547 US202318232547A US2023390387A1 US 20230390387 A1 US20230390387 A1 US 20230390387A1 US 202318232547 A US202318232547 A US 202318232547A US 2023390387 A1 US2023390387 A1 US 2023390387A1
- Authority
- US
- United States
- Prior art keywords
- mixed allergen
- product
- cfu
- allergen product
- dry heat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013566 allergen Substances 0.000 title claims abstract description 236
- 238000000034 method Methods 0.000 title claims abstract description 49
- 239000000203 mixture Substances 0.000 title description 14
- 230000010076 replication Effects 0.000 claims abstract description 15
- 239000000463 material Substances 0.000 claims description 90
- 230000001954 sterilising effect Effects 0.000 claims description 79
- 239000013568 food allergen Substances 0.000 claims description 69
- 238000004659 sterilization and disinfection Methods 0.000 claims description 68
- 102000004169 proteins and genes Human genes 0.000 claims description 42
- 108090000623 proteins and genes Proteins 0.000 claims description 42
- 238000002156 mixing Methods 0.000 claims description 35
- 230000009467 reduction Effects 0.000 claims description 32
- 239000000523 sample Substances 0.000 claims description 30
- 238000010438 heat treatment Methods 0.000 claims description 27
- 238000004519 manufacturing process Methods 0.000 claims description 21
- 230000000694 effects Effects 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000002245 particle Substances 0.000 claims description 14
- 244000105624 Arachis hypogaea Species 0.000 claims description 11
- 235000013601 eggs Nutrition 0.000 claims description 11
- 235000020232 peanut Nutrition 0.000 claims description 11
- 244000144725 Amygdalus communis Species 0.000 claims description 10
- 235000011437 Amygdalus communis Nutrition 0.000 claims description 10
- 244000226021 Anacardium occidentale Species 0.000 claims description 10
- 235000017060 Arachis glabrata Nutrition 0.000 claims description 10
- 235000010777 Arachis hypogaea Nutrition 0.000 claims description 10
- 235000018262 Arachis monticola Nutrition 0.000 claims description 10
- 241000972773 Aulopiformes Species 0.000 claims description 10
- 235000009025 Carya illinoensis Nutrition 0.000 claims description 10
- 244000068645 Carya illinoensis Species 0.000 claims description 10
- 235000001543 Corylus americana Nutrition 0.000 claims description 10
- 235000007466 Corylus avellana Nutrition 0.000 claims description 10
- 235000010469 Glycine max Nutrition 0.000 claims description 10
- 240000007049 Juglans regia Species 0.000 claims description 10
- 235000009496 Juglans regia Nutrition 0.000 claims description 10
- 240000006711 Pistacia vera Species 0.000 claims description 10
- 235000003447 Pistacia vera Nutrition 0.000 claims description 10
- 235000003434 Sesamum indicum Nutrition 0.000 claims description 10
- 235000021307 Triticum Nutrition 0.000 claims description 10
- 241000209140 Triticum Species 0.000 claims description 10
- 235000020224 almond Nutrition 0.000 claims description 10
- 235000020226 cashew nut Nutrition 0.000 claims description 10
- 235000020233 pistachio Nutrition 0.000 claims description 10
- 235000019515 salmon Nutrition 0.000 claims description 10
- 235000020234 walnut Nutrition 0.000 claims description 10
- 240000009226 Corylus americana Species 0.000 claims description 9
- 241000238557 Decapoda Species 0.000 claims description 9
- 241000607142 Salmonella Species 0.000 claims description 9
- 235000013336 milk Nutrition 0.000 claims description 9
- 239000008267 milk Substances 0.000 claims description 9
- 210000004080 milk Anatomy 0.000 claims description 9
- 238000004806 packaging method and process Methods 0.000 claims description 9
- 235000007319 Avena orientalis Nutrition 0.000 claims description 8
- 241000209763 Avena sativa Species 0.000 claims description 8
- 235000007558 Avena sp Nutrition 0.000 claims description 8
- 241000989055 Cronobacter Species 0.000 claims description 8
- 241000276438 Gadus morhua Species 0.000 claims description 8
- 230000001580 bacterial effect Effects 0.000 claims description 8
- 235000019516 cod Nutrition 0.000 claims description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 7
- 239000004067 bulking agent Substances 0.000 claims description 7
- 241000588724 Escherichia coli Species 0.000 claims description 5
- 238000003556 assay Methods 0.000 claims description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 5
- 241000588921 Enterobacteriaceae Species 0.000 claims description 4
- 241000186781 Listeria Species 0.000 claims description 4
- 241000191967 Staphylococcus aureus Species 0.000 claims description 3
- 244000000231 Sesamum indicum Species 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 description 35
- 238000010200 validation analysis Methods 0.000 description 18
- 238000011282 treatment Methods 0.000 description 16
- 239000000843 powder Substances 0.000 description 15
- 235000013305 food Nutrition 0.000 description 14
- 206010020751 Hypersensitivity Diseases 0.000 description 11
- 230000008569 process Effects 0.000 description 9
- 241000207961 Sesamum Species 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000000499 gel Substances 0.000 description 7
- 230000002009 allergenic effect Effects 0.000 description 6
- 230000007815 allergy Effects 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 6
- 208000004262 Food Hypersensitivity Diseases 0.000 description 5
- -1 Onc k 5 Proteins 0.000 description 5
- 235000020932 food allergy Nutrition 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 108010003571 Nut Proteins Proteins 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 235000013406 prebiotics Nutrition 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 230000000529 probiotic effect Effects 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 206010016946 Food allergy Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930003316 Vitamin D Natural products 0.000 description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 3
- 229940107187 fructooligosaccharide Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000003345 natural gas Substances 0.000 description 3
- 239000005022 packaging material Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 235000019166 vitamin D Nutrition 0.000 description 3
- 239000011710 vitamin D Substances 0.000 description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 description 3
- 229940046008 vitamin d Drugs 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- 241001505572 Anaerostipes caccae Species 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000193749 Bacillus coagulans Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241001608472 Bifidobacterium longum Species 0.000 description 2
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 2
- 101000617728 Homo sapiens Pregnancy-specific beta-1-glycoprotein 9 Proteins 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- 101000798429 Pinus strobus Putative 2-Cys peroxiredoxin BAS1 Proteins 0.000 description 2
- 101001136140 Pinus strobus Putative oxygen-evolving enhancer protein 2 Proteins 0.000 description 2
- 101000600488 Pinus strobus Putative phosphoglycerate kinase Proteins 0.000 description 2
- 102100021983 Pregnancy-specific beta-1-glycoprotein 9 Human genes 0.000 description 2
- 208000036071 Rhinorrhea Diseases 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- 108010073771 Soybean Proteins Proteins 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 102100038968 WAP four-disulfide core domain protein 1 Human genes 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 229940054340 bacillus coagulans Drugs 0.000 description 2
- 229940009291 bifidobacterium longum Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013350 formula milk Nutrition 0.000 description 2
- 230000005931 immune cell recruitment Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 235000014571 nuts Nutrition 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 229910052761 rare earth metal Inorganic materials 0.000 description 2
- 150000002910 rare earth metals Chemical class 0.000 description 2
- 229940001941 soy protein Drugs 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- 231100000611 venom Toxicity 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 description 1
- FVVCFHXLWDDRHG-UPLOTWCNSA-N (2s,3r,4s,5r,6r)-2-[(2r,3s,4r,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 FVVCFHXLWDDRHG-UPLOTWCNSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000143060 Americamysis bahia Species 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000205479 Bertholletia excelsa Species 0.000 description 1
- 235000012284 Bertholletia excelsa Nutrition 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 235000004936 Bromus mango Nutrition 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 240000007154 Coffea arabica Species 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 240000007582 Corylus avellana Species 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 101100539403 Drosophila melanogaster sgl gene Proteins 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010002537 Fruit Proteins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 244000070406 Malus silvestris Species 0.000 description 1
- 240000007228 Mangifera indica Species 0.000 description 1
- 235000014826 Mangifera indica Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000005135 Micromeria juliana Nutrition 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 240000002114 Satureja hortensis Species 0.000 description 1
- 235000007315 Satureja hortensis Nutrition 0.000 description 1
- 235000009184 Spondias indica Nutrition 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 206010057040 Temperature intolerance Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 229930003761 Vitamin B9 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 235000021015 bananas Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 229940009289 bifidobacterium lactis Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019705 chickpea protein Nutrition 0.000 description 1
- 235000010675 chips/crisps Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003256 environmental substance Substances 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000021022 fresh fruits Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008543 heat sensitivity Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000002919 insect venom Substances 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- 230000005722 itchiness Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000013528 metallic particle Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 238000011012 sanitization Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000012358 sourcing Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 235000021012 strawberries Nutrition 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- 229940074409 trehalose dihydrate Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 235000019159 vitamin B9 Nutrition 0.000 description 1
- 239000011727 vitamin B9 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/02—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by heating materials in packages which are progressively transported, continuously or stepwise, through the apparatus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/10—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by heating materials in packages which are not progressively transported through the apparatus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/16—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by heating loose unpacked materials
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
Definitions
- Allergy is a disorder of the immune system characterized by the occurrence of allergic reactions to normally harmless environmental substances. Allergies are caused by allergens, which may be present in a wide variety of sources including, but not limited to, pollens or other plant components, dust, molds or fungi, foods, additives, latex, transfusions, animal or bird danders, insect venoms, radiocontrast medium, medications, or chemicals. Common allergic reactions include eczema, hives, hay fever, asthma, and reactions to venoms. Mild allergies, like hay fever, are highly prevalent in the human population and cause symptoms such as allergic conjunctivitis, itchiness, and runny nose. In some people, severe allergies to environmental allergens, dietary allergens, or medication may result in life-threatening anaphylactic reactions if left untreated.
- a food allergy is an adverse immune response to a food allergen, for example, a food protein.
- a food allergen for example, a food protein.
- Common food allergens are found in shellfish, peanuts, tree nuts, fish, milk, eggs, soy and fresh fruits such as strawberries, mangoes, bananas, and apples.
- Immunoglobulin E (IgE)-mediated food allergies are classified as type-I immediate hypersensitivity reactions.
- allergic reactions have an acute onset (from seconds to one hour) and the accompanying symptoms may include: angioedema (soft tissue swelling of the eyelids, face, lips, tongue, larynx and trachea); hives; itching of the mouth, throat, eyes, and skin; gastrointestinal symptoms such as nausea, vomiting, diarrhea, stomach cramps, and abdominal pain; rhinorrhea or nasal congestion; wheezing; shortness of breath; difficulty swallowing; and anaphylaxis, a severe, whole-body allergic reaction that can result in death.
- angioedema soft tissue swelling of the eyelids, face, lips, tongue, larynx and trachea
- hives itching of the mouth, throat, eyes, and skin
- gastrointestinal symptoms such as nausea, vomiting, diarrhea, stomach cramps, and abdominal pain
- rhinorrhea or nasal congestion wheezing
- shortness of breath difficulty swallowing
- allergen compositions that can prevent and/or treat allergies, and methods for making allergen compositions to prevent and/or treat allergies.
- This disclosure is directed, at least in part, to a method of making a mixed allergen product substantially free of replication viable organisms.
- the method comprises: providing bulk mixed allergen material comprising 2 to 20 individual complete food allergens; and sterilizing the bulk mixed allergen material by dry heat sterilization, thereby obtaining the mixed allergen product.
- a method further comprises providing 2 to 20 individual complete food allergens and blending the 2 to 20 individual complete food allergens together to obtain the bulk mixed allergen material.
- the disclosure provides a method, wherein the 2 to 20 individual complete food allergens are selected from the group consisting of almond, cashew, cod, egg, hazelnut, milk, oat, peanut, pecan, pistachio, salmon, sesame, shrimp, soy, walnut, and wheat.
- the disclosure provides a method, wherein the blending further comprises blending the 2 to 20 individual complete food allergens with one or more than one bulking agent.
- blending comprises loading 2 to 20 individual complete food allergens into a ribbon blender set at about 10 Hz to about 50 Hz for about 10 minutes to about 50 minutes.
- the bulk mixed allergen material is discharged into lined drums after blending.
- a method of the present disclosure further comprises filtering the mixed allergen product.
- filtering comprises passing the mixed allergen product through a screen ranging from a #5 mesh (US) screen to a #10 mesh (US) screen on a shaker for about 1 minute to about 10 minutes.
- a method of the present disclosure further comprises passing the mixed allergen product through a rare earth magnet, metal detector, and metal separator.
- a described method of the present disclosure provides applying dry heat sterilization, wherein the dry heat sterilization is at a temperature of about 65° C. to about 175° C. for about 18 hours to about 72 hours.
- the dry heat sterilization comprises using a sterilization system having a furnace and a heating chamber, wherein the furnace provides about 250,000 BTUs to about 750,000 BTUs of heat to the heating chamber.
- the bulk mixed allergen material is first packaged into thermoresistant packaging before dry heat sterilization.
- temperature probes are placed with the bulk mixed allergen material during sterilizing to monitor the temperature of the dry heat sterilization.
- the mixed allergen product has at least about a 1 log reduction to at least about a 4 log reduction in aerobic bacterial organism plate counts as compared to corresponding bulk mixed allergen material that has not been sterilized. In some embodiments, the mixed allergen product has less than about 10,000 CFU/g of aerobic bacterial organisms. In other embodiments, the mixed allergen product has less than about 10 CFU/g of coliforms, Escherichia coli , Enterobacteriaceae, mold, Staphylococcus aureus , and yeast. In certain embodiments, the mixed allergen product has less than about 10 CFU/g of Salmonella . In certain embodiments, the mixed allergen product has less than about 10 CFU/g of Cronobacter .
- the mixed allergen product is negative in PCR-based assays for Listeria species, Cronobacter species and Salmonella species per 25 g of mixed allergen product, 25 g of mixed allergen product, and 375 g of mixed allergen product, respectively.
- the mixed allergen product has a fat content of about 10% to about 20% by weight.
- protein integrity of the mixed allergen product is substantially similar to protein integrity of corresponding bulk mixed allergen material that has not been sterilized. In some embodiments, the protein integrity of the mixed allergen product is determined by SDS-PAGE.
- the mixed allergen product has a protein content of about 40% to about 50% by weight.
- the mixed allergen product has about 1% to about 10% moisture by weight. In other embodiments, the mixed allergen product has a water activity of about 0.1 to about 0.6.
- the mixed allergen product comprises less than about 10% by weight of particles having a diameter greater than 500 m.
- the mixed allergen product is darker in color as compared to corresponding bulk mixed allergen material that has not been sterilized. In other embodiments, the mixed allergen product has a substantially similar taste profile as compared to corresponding bulk mixed allergen material that has not been sterilized.
- a described method of the present disclosure comprises one or more than one further application of dry heat sterilization.
- the present disclosure describes a method of making a mixed allergen product substantially free of replication viable organisms, comprising: providing 2 to 20 individual complete food allergens; sterilizing each of the 2 to 20 individual complete food allergens by dry heat sterilization, thereby obtaining 2 to 20 sterilized individual complete food allergens; and blending the 2 to 20 sterilized individual complete food allergens together, thereby obtaining the mixed allergen product.
- the present disclosure describes a method of making a mixed allergen product substantially free of replication viable organisms, wherein the method further comprises blending the mixed allergen product with one or more than one probiotic selected from the group consisting of Lactobacillus rhamnosus, Anaerostipes caccae , and Bifidobactierium longum.
- the mixed allergen product is further blended with one or more than one prebiotic, for example, wherein the prebiotic is fructooligosaccharide.
- FIG. 1 is a macroscopic image of non-sterilized bulk mixed allergen material sample and bulk mixed allergen material samples which have been heated in a laboratory oven for 5 minutes at 95° C., 105° C., 110° C., or 120° C.
- FIG. 2 A is a schematic showing the placement of pallets and sample boxes containing thermoresistant bags of bulk mixed allergen material in a dry heat sterilization chamber for validation trial 1.
- B3 of pallets 3, 4 and 12 have chamber probes placed inside the boxes for temperature monitoring.
- B4 of pallets 7 and 8 have chamber probes placed outside the boxes, and B4 of pallet 11 has a chamber probe placed inside the box.
- FIG. 2 B is a schematic showing the placement of pallets and sample boxes containing thermoresistant bags of bulk mixed allergen material in a dry heat sterilization chamber for validation trial 2.
- B3 of pallets 5 and 14 have chamber probes placed inside the boxes for temperature monitoring.
- Shaded boxes indicate empty boxes without thermoresistant bags containing bulk mixed allergen material.
- Asterisks (“*”) indicate boxes having two thermoresistant bags containing bulk mixed allergen material.
- “P” indicates boxes having a
- FIG. 3 A is line graph showing the temperature profile of the dry heat sterilization chamber during validation trial 1.
- FIG. 3 B is line graph showing the temperature profile of the dry heat sterilization chamber during validation trial 2.
- Each line represents the temperature readings of a single chamber probe or MadgeTech probe.
- replication viable organisms it is meant organisms that are capable of multiplying, reproducing, propagating, and/or producing colony forming units (CFU) on a plate culture.
- CFU colony forming units
- sterilization it is meant a process that is capable of substantially reducing the number of replication viable organisms.
- an “individual complete food allergen” refers to a food substance containing all possible antigenic components for said food substance (for example, allergenic proteins).
- Individual complete food allergens may include, but are not limited to, unprocessed or processed food substances, concentrated food substances, and isolated food substances.
- Allergenic proteins are antigenic components of food allergens that are, either directly or indirectly, responsible for eliciting a biological allergic response. Allergenic proteins may include, but are not limited to, nut proteins such as hazelnut proteins (e.g., Cor a 1, Cor a 2, Cor a 6, Cor a 8, Cor a 9, Cor a 10, Cor a 11, Cor a 12, Cor a 13, and Cor a 14), cashew proteins (e.g., Ana o 1, Ana o 2, and Ana o 3), pistachio proteins (e.g., Pis v 1, Pis v 2, Pis v 3, Pis v 4, and Pis v 5), walnut proteins (e.g., Jug r 1, Jug r 2, Jug r 3, Jug r 4, Jug r 5, Jug r 6, Jug r 7, and Jug r 8, Jug n1, Jug n 2, and Jug n 4), pecan proteins (e.g., Car i 1, Car i
- Allergenic proteins may also include, but are not limited to, animal proteins such as egg proteins (e.g., Gal d 1, Gal d 2, Gal d 3, Gal d 4, Gal d 5, Gal d 6, Gal d 7, Gal d 8, Gal d 9, Gal d 10), milk proteins (e.g., Bos d 2, Bos d 3, Bos d 4, Bos d 5, Bos d, 6, Bos d 7, Bos d 8, Bos d 9, Bos d 10, Bos d 11, and Bos d 12), salmon proteins (e.g., Onc k 5, Sal s 1, Sal s 2, and Sal s 3), cod proteins (e.g., pGad c 1, Gad m 1, Gad m 2, and Gad m 3), shrimp proteins (e.g., Cra c 1, Cra c 2, Cra c 4, Cra c 5, Cra c 6, Cra c 8, Lit v 1, Lit v 2, Lig v 3, Lit v 4, Met e 1, Pan
- Allergenic proteins may further include, but are not limited to, non-nut plant proteins such as wheat proteins (e.g., Tri a 12, Tri a 14, Tri a 15, Tri a 17, Tri a 18, Tri a 19, Tri a 20, Tri a 21, Tri a 25, Tri a 26, Tri a 27, Tri a 28, Tri a 29, Tri a 30, Tri a 31, Tri a 32, Tri a 33, Tri a 34, Tri a 35, Tri a 36, Tri a 37, Tri a 39, Tri a 40, Tri a 41, Tri a 42, Tri a 43, Tri a 44, and Tri a 45), soy proteins (e.g., Gly m 1, Gly m 1.0101, Gly m 2, Gly m 3, Gly m 4, Gly m 5, Gly m 6, Gly m 7, and Gly m 8), chickpea proteins, sesame seed proteins (e.g., Ses i 1, Ses i 2, Ses i 3, Ses i 4, Ses
- a method of making a mixed allergen product substantially free of replication viable organisms comprising: providing bulk mixed allergen material comprising 2 to 20 individual complete food allergens; and sterilizing the bulk mixed allergen material by dry heat sterilization, thereby obtaining the mixed allergen product.
- bulk mixed allergen material comprises 2 to 20 individual complete food allergens, for example, 4 to 20, 6 to 20, 8 to 20, 10 to 20, 12 to 20, 14 to 20, 16 to 20, 18 to 20, 2 to 18, 4 to 18, 6 to 18, 8 to 18, 10 to 18, 12 to 18, 14 to 18, 16 to 18, 2 to 16, 4 to 16, 6 to 16, 8 to 16, 10 to 16, 12 to 16, or 14 to 16 individual complete food allergens.
- bulk mixed allergen material may comprise 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 individual complete food allergens.
- bulk mixed allergen material comprises 15 or 16 individual complete food allergens.
- the individual complete food allergens are selected from the group consisting of nut, seed, legume, egg, dairy, fish and crustacean.
- the individual complete food allergens are selected from the group consisting of almond, cashew, hazelnut, peanut, pecan, pistachio, walnut, sesame, soy, egg, milk, oat, wheat, cod, salmon, and shrimp.
- the individual complete food allergens are almond, cashew, hazelnut, peanut, pecan, pistachio, walnut, sesame, soy, egg, milk, oat, wheat, cod, salmon, and shrimp. It is contemplated that the individual complete food allergens may be provided as a meal, flour, powder, and/or protein concentrate.
- a described method further comprises providing 2 to 20 individual complete food allergens, and blending the 2 to 20 individual complete food allergens together to obtain bulk mixed allergen material.
- two or more individual complete food allergens may be provided in combination prior to blending.
- 2 to 20, 4 to 20, 6 to 20, 8 to 20, 10 to 20, 12 to 20, 14 to 20, 16 to 20, 18 to 20, 2 to 18, 4 to 18, 6 to 18, 8 to 18, 10 to 18, 12 to 18, 14 to 18, 16 to 18, 2 to 16, 4 to 16, 6 to 16, 8 to 16, 10 to 16, 12 to 16, or 14 to 16 individual complete food allergens may be provided in combination prior to blending.
- 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 individual complete food allergens may be provided in combination prior to blending.
- blending may comprise one or more than one blending steps to obtain bulk mixed allergen material.
- individual complete food allergens may be blended in 1 to 19, 1 to 17, 1 to 15, 1 to 13, 1 to 11, 1 to 9, 1 to 7, 1 to 5, or 1 to 3 blending steps.
- blending comprises mixing individual complete food allergens in a single blending step.
- bulk mixed allergen material is sterilized by dry heat sterilization. It will be appreciated that sterilizing may further comprise one or more than one additional application of dry heat sterilization, to inactivate heat-resistant spores.
- dry heat may be supplied to a treatment chamber of a sterilization system within which bulk mixed allergen material is held or is conveyed, wherein the treatment chamber may be heated to a temperature of about 65° C. to about 175° C.
- the treatment chamber may be heated to about 65° C. to about 80° C., about 65° C. to about 120° C., about 100° C. to about 150° C., or about 125° C. to about 175° C.
- the treatment chamber may be heated to a temperature of about 65° C., about 66° C., about 67° C., about 68° C., about 69° C., about 70° C., about 71° C., about 72° C., about 73° C., about 74° C., about 75° C., about 85° C., about 95° C., about 105° C., about 115° C., about 125° C., about 135° C., about 145° C., about 155° C., about 165° C., or about 175° C.
- dry heat may be applied to bulk mixed allergen material for about 3 minutes to about 72 hours.
- dry heat may be applied for about 3 minutes to about 72 hours, about 30 minutes to about 72 hours, about 12 hours to about 72 hours, about 18 hours to about 72 hours, about 24 hours to about 72 hours, about 30 hours to about 72 hours, about 36 hours to about 72 hours, about 42 hours to about 72 hours, about 48 hours to about 72 hours, about 54 hours to about 72 hours, about 60 hours to about 72 hours, or about 66 hours to about 72 hours.
- dry heat may be applied to bulk mixed allergen material for about 30 minutes, about 45 minutes, about 60 minutes, about 75 minutes, about 90 minutes, about 105 minutes, about 120 minutes, about 12 hours, about 18 hours, about 24 hours, about 30 hours, about 36 hours, about 42 hours, about 48 hours, about 54 hours, about 60 hours, about 66 hours, or about 72 hours.
- dry heat may be provided to a treatment chamber of a sterilization system by multiple natural gas fired furnaces that provide about 250,000 BTUs to about 750,000 BTUs of heat to the treatment chamber.
- about 250,000 BTUs, about 300,000 BTUs, about 350,000 BTUs, about 400,000 BTUs, about 450,000 BTUs, about 500,000 BTUs, about 550,000 BTUs, about 600,000 BTUs, about 650,000 BTUs, about 700,000 BTUs, or about 750,000 BTUs of heat may be provided to the treatment chamber.
- thermoresistant is understood to mean that applying the same temperature and duration of heat to the packaging material as concurrently applied to the bulk mixed allergen material packaged therein, does not cause changes in the packaging material that affect its integrity and functionality as a barrier to chemical or microbial contamination.
- thermoresistant is understood to mean that applying the same temperature and duration of heat to the packaging material as concurrently applied to the bulk mixed allergen material packaged therein, does not alter the packaging to cause a chemical in the packaging to be added to the bulk mixed allergen material packaged therein.
- the thermoresistant packaging may include, but is not limited to, bulk bags, pouches, or stickpacks.
- the thermoresistant packaging may be placed in boxes and/or on pallets or racks within a heating chamber for dry heat sterilization.
- blending may comprise loading 2 to 20 individual complete food allergens (e.g., 4 to 20, 6 to 20, 8 to 20, 10 to 20, 12 to 20, 14 to 20, 16 to 20, 18 to 20, 2 to 18, 4 to 18, 6 to 18, 8 to 18, 10 to 18, 12 to 18, 14 to 18, 16 to 18, 2 to 16, 4 to 16, 6 to 16, 8 to 16, 10 to 16, 12 to 16, or 14 to 16 individual complete food allergens) into a mechanical blender or mixer.
- the mechanical blender or mixer may be selected from, but not limited to: a ribbon blender; a paddle blender; a plow blender; a fluidizing blender; an intensive mixer; a vacuum mixer; a conical mixer; a rotary batch mixer; and a double shaft mixer.
- the individual complete food allergens are loaded into a ribbon blender.
- blending by loading the individual complete food allergens into a mechanical blender or mixer reduces grittiness, reduces the number of large particles, and increases homogeneity.
- each individual complete food allergen may be loaded into the mechanical blender or mixer in various amounts including, for example, but not limited to: about 5 kg to about 100 kg; about 10 kg to about 90 kg; about 15 kg to about 80 kg; about 20 kg to about 70 kg; about 25 kg to about 60 kg; and about 30 kg to about 50 kg.
- the mechanical blender or mixer may accommodate various total combined amounts of complete food allergens. In certain embodiments, for example, the mechanical blender or mixer may accommodate a total combined amount of complete food allergens of about 100 kg to about 2200 kg or about 500 kg to about 2000 kg.
- the mechanical blender or mixer may accommodate an amount of about 500 kg, about 600 kg, about 700 kg, about 800 kg, about 900 kg, about 1000 kg, about 1100 kg, about 1200 kg, about 1500 kg, about 1600 kg, about 1700 kg, about 1800 kg, about 1900 kg, or about 2000 kg of total combined complete food allergens.
- the settings of the mechanical blender or mixer may be adjusted so as to achieve optimal blending and/or mixing of the individual complete food allergens.
- the mechanical blender may be set to about 10 Hz to about 50 Hz (e.g., about 15 Hz to about 45 Hz, about 20 Hz to about 40 Hz, or about 25 Hz to about 35 Hz).
- the mechanical blender may also be set to operate for various lengths of time.
- the mechanical blender may blend the individual food allergens for about 5 minutes to about 30 minutes, about 7.5 minutes to about 25 minutes, or about 10 minutes to about 20 minutes.
- the mechanical blender or mixer is a 1000 kg capacity ribbon blender and blends the individual complete food allergens at 30 Hz for 15 minutes.
- a method of the present disclosure further comprises blending the 2 to 20 individual complete food allergens with one or more than one bulking agents.
- Contemplated bulking agents may include any bulking agent described herein.
- the bulking agent comprises a sugar, for example, sucrose, maltodextrin, trehalose, trehalose dihydrate, isomalt, mannitol, lactose, dextrose, fructose, raffinose, or any combination thereof.
- the bulking agent comprises maltodextrin, or sucrose, or a combination thereof.
- bulk mixed allergen material may be discharged from a mechanical blender or mixer into lined drums before being loaded for sterilization.
- the bulk mixed allergen material discharged into lined drums may be packaged in bags or pouches.
- a mixed allergen product may be filtered through a screen ranging from a #5 mesh (US) screen to a #10 mesh (US) screen on a shaker for about 1 minute to about 10 minutes.
- the screen may be a #5 mesh (US) screen, a #6 mesh (US) screen, a #7 mesh (US) screen, a #8 mesh (US) screen, a #9 mesh (US) screen, or a #10 mesh (US) screen.
- the mixed allergen product is filtered through a screen ranging from a #5 mesh (US) screen to a #10 mesh (US) screen on a shaker for about 3 minutes.
- a method of making a mixed allergen product may further comprise magnetically sifting a mixed allergen product to remove metallic particles.
- magnetic sifting may comprise passing mixed allergen product through a rare earth magnet, a metal detector, and/or a metal separator.
- the metal detector may detect stainless steel particles at least about 2 mm to about 2.5 mm in size, ferrous particles at least about 1.5 mm to about 2 mm in size, and non-ferrous particles with a sensitivity of about 1.5 to 2 parts per million.
- a method of making a mixed allergen product may be a continuous process, wherein the total completion time for the method is about 3 minutes to about 72 hours, about 30 minutes to about 72 hours, about 12 hours to about 72 hours, about 18 hours to about 72 hours, about 24 hours to about 72 hours, about 30 hours to about 72 hours, about 36 hours to about 72 hours, about 42 hours to about 72 hours, about 48 hours to about 72 hours, about 54 hours to about 72 hours, about 60 hours to about 72 hours, or about 66 hours to about 72 hours.
- the total completion time for the method is about 30 minutes, about 45 minutes, about 60 minutes, about 75 minutes, about 90 minutes, about 105 minutes, about 120 minutes, about 12 hours, about 18 hours, about 24 hours, about 30 hours, about 36 hours, about 42 hours, about 48 hours, about 54 hours, about 60 hours, about 66 hours, or about 72 hours.
- sterilizing bulk mixed allergen material by dry heat sterilization produces a mixed allergen product that is substantially free of replication viable organisms.
- a mixed allergen product of the present disclosure is substantially free of replication viable bacteria, yeast, and/or molds.
- a mixed allergen product may have: at least about a 1 log reduction to at least about a 9 log reduction; at least about a 1 log reduction to about a 4 log reduction; at least about a 1 log reduction to about a 5 log reduction; at least about a 1 log reduction to about a 6 log reduction; at least about a 1 log reduction to about a 7 log reduction; at least about a 1 log reduction to about a 8 log reduction, or at least about a 3 log reduction to about a 9 log reduction in aerobic bacterial organism plate counts as compared to a corresponding bulk mixed allergen material that has not been sterilized.
- a mixed allergen product may have at least about a 1 log reduction, at least about a 2 log reduction, at least about a 3 log reduction, at least about a 4 log reduction, at least about a 5 log reduction, at least about a 6 log reduction, at least about a 7 log reduction, at least about a 8 log reduction, or at least about a 9 log reduction.
- aerobic bacterial organism plate counts as compared to a corresponding bulk mixed allergen material that has not been sterilized.
- a mixed allergen product has less than about 100,000 CFU/g, 10,000 CFU/g, less than about 1,000 CFU/g, less than about 100 CFU/g, or less than about 10 CFU/g of aerobic bacterial organisms.
- a mixed allergen product has less than about 100 CFU/g, less than about 10 CFU/g, or less than about 1 CFU/g of coliforms. In yet another example, a mixed allergen product may have less than about 10 CFU/g of a pathogenic microbial strain. For example, a mixed allergen product has less than about 100 CFU/g, less than about 10 CFU/g, or less than about 1 CFU/g of Escherichia coli . In a further example, a mixed allergen product has less than about 100 CFU/g, less than about 10 CFU/g, or less than about 1 CFU/g of Enterobacteriaceae.
- a mixed allergen product has less than about 100 CFU/g, or less than about 10 CFU/g of Salmonella . In another example, a mixed allergen product has less than about 100 CFU/g, or less than about 10 CFU/g of Cronobacter . In yet another example, a mixed allergen product is negative for Listeria species or Cronobacter species per 25 g sample of said mixed allergen product as determined by a PCR-based assay. In another example, a mixed allergen product has less than about 100 CFU/g, less than about 10 CFU/g, or less than about 1 CFU/g of mold.
- a mixed allergen product is negative for Salmonella species per 375 g sample of said mixed allergen product as determined by a PCR-based assay.
- a mixed allergen product has less than about 100 CFU/g, less than about 10 CFU/g, or less than about 1 CFU/g of Staphylococcus aureus .
- a mixed allergen product has less than about 100 CFU/g, less than about 10 CFU/g, or less than about 1 CFU/g of yeast.
- a mixed allergen product of the present disclosure has a fat content of at least about 5% by weight.
- a mixed allergen product may have a fat content of about 10% to about 20% by weight.
- a mixed allergen product may have a fat content of about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, or about 20% by weight.
- a sterilized mixed allergen product has substantially the same protein integrity as a corresponding bulk mixed allergen material that has not been sterilized.
- protein integrity is determined by SDS-PAGE, wherein mixed allergen product has substantially similar protein bands, protein band distribution, and protein band intensity as non-sterilized bulk mixed allergen material.
- allergen effect is understood to mean an immune reaction to one or more than one antigenic component characterized by, but not limited to, immune cell activation, production of cytokines, and production of IgE.
- mixed allergen product has a substantially similar allergen effect upon being consumed by an individual as consumption of a substantially similar protein amount of corresponding bulk mixed allergen material that has not been sterilized.
- an allergen effect is measured by the production of IgE or cytokines, or measuring immune cell activation in response to consumption of bulk mixed allergen material or mixed allergen product by an individual.
- the allergen effect is measured by an in vitro immune response, for example, measuring the production of IgE or cytokines, or measuring activation of immune cell cultures following treatment with bulk mixed allergen material or mixed allergen product.
- a mixed allergen product of the present disclosure has a protein content of about 40% to about 50% by weight.
- a mixed allergen product may have a protein content of about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, or about 50% by weight.
- a mixed allergen product of the present disclosure has about 1% to about 10% moisture by weight.
- a mixed allergen product may have about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10% moisture by weight.
- a mixed allergen product of the present disclosure has about 0.1 to about 0.6 water activity.
- Water activity is understood as the ratio between the vapor pressure of the mixed allergen product and the vapor pressure of distilled water under identical conditions. It will be appreciated that water activity is a measure of the water that is not bound to the molecules of the mixed allergen product and thus capable of supporting growth of bacteria, yeast and mold. Furthermore, it will be appreciated that water activity may be measured using suitable electronic instruments such as moisture meters, moisture-humidity meters, hygrometers, and relative humidity systems.
- a mixed allergen product of the present disclosure has less than about 10% by weight of particles having a diameter greater than 500 ⁇ m.
- a mixed allergen product of the present disclosure has a substantially similar taste profile as compared to corresponding bulk mixed allergen material that has not been sterilized.
- a mixed allergen product may have one or more than one flavor selected from, but not limited to, savory, nutty, marine, roasted, and brown.
- a mixed allergen product does not have any off-flavors from processing.
- a method of making a mixed allergen product substantially free of replication viable organisms is contemplated, wherein 2 to 20 individual food allergens are sterilized by dry heat sterilization before blending to obtain a mixed allergen product.
- a method of making a mixed allergen product further comprises blending the mixed allergen product with one or more than one probiotic selected from a group including, but not limited to, Lactobacillus species, Bifidobacterium species, Anacaerostipes species, and Bacillus species.
- one or more probiotic may be selected from a group including, but not limited to Lactobacillus rhamnosis, Anaerostipes caccae, Bifidobacterium longum, Bifidobacterium lactis, Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus brevis, Lactobacillus salivarius, Lactococcus lactis, Bacillus coagulans, Lactobacillus bulgaricus, Lactobacillus gasseri, Lactobacillus paracasei, Bacillus coagulans and Bifidobacterium bifidum .
- a method of making a mixed allergen product further comprises blending the mixed allergen product with Lactobacillus rhamnosis and/or Bifidobacterium longum .
- probiotic refers to a culture (pure or mixed), comprising microorganisms which, when ingested, beneficially affect the host.
- a method of making a mixed allergen product further comprises blending the mixed allergen product with one or more than one prebiotic selected from a group including, but not limited to, fructooligosaccharide, inulin, isomalto-oligosaccharide, lactilol, lactosucrose, lactulose, pyrodextrin, soybean oligosaccharide, xylooligosaccharide, transgalactooligosaccharide, oligosaccharide, soluble corn fiber, beta-glucan, oligofructose, and bipolymer.
- a group including, but not limited to, fructooligosaccharide, inulin, isomalto-oligosaccharide, lactilol, lactosucrose, lactulose, pyrodextrin, soybean oligosaccharide, xylooligosaccharide, transgalactooligosaccharide, oligo
- a method of making a mixed allergen product further comprises blending the mixed allergen product with fructooligosaccharide.
- prebiotic refers to a specific dietary food or nutrient that promotes the growth, proliferation, and/or activity of a specific, desirable, bacterial strain.
- a disclosed mixed allergen product may further include one or more vitamins, as desired.
- Vitamins that may be present include, for example, vitamin A (e.g., in an amount ranging from about 1 to about 35,000 IU), vitamin C (e.g., in an amount ranging from about 1 to about 1,000 mg), vitamin D (e.g., in an amount ranging from about 1 to about 4,000 IU, i.e.
- vitamin E e.g., in an amount ranging from about 1 to about 450 IU
- vitamin K e.g., in an amount ranging from about 1 to about 250 ⁇ g
- vitamin B-1 thiamin; e.g., in amount ranging from about 1 to about 15 mg
- vitamin B-2 riboflavin; e.g., in an amount ranging from about 1 to about 17 mg
- vitamin B-3 niacin; e.g., in an amount ranging from about 1 to about 200 mg
- vitamin B-5 pantothenic acid; e.g., in an amount ranging from about 1 to about 100 mg
- vitamin B-6 pyridoxine; e.g., in an amount ranging from about 1 to about 30 mg
- vitamin B-9 folic acid; e.g., in an amount ranging from about 1 to about 4,000 ⁇ g
- vitamin B-12 cobalamin; e.g., in an amount ranging from about 1 to about 250 ⁇
- a method of making a mixed allergen product wherein the mixed allergen product is further mixed with a physiologically acceptable delivery vehicle to produce a physiologically acceptable composition.
- Mixed allergen products can be further incorporated into a variety of formulations for administration to a subject. More particularly, a mixed allergen product can be formulated into a physiological acceptable composition by combination with appropriate, physiologically acceptable carriers or diluents, for example, a vegetable oil.
- a disclosed mixed allergen product is designed for oral immunotherapeutic treatment of food allergy in a child or adult, for example, as dispersible powders or granules, foods, tablets, troches, lozenges, gummies, emulsions, etc.
- Compositions intended for oral use may be prepared according to any convenient protocol for the manufacture of oral compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents (e.g., glycerol, propylene glycol, sorbitol, or sucrose), flavoring agents, coloring agents and preserving agents in order to provide palatable preparations.
- a method of making a mixed allergen product wherein the mixed allergen product is mixed or incorporated with food to which a child or adult is not allergic.
- foods may include, but are not limited to: baby or infant formula, baby food (e.g., pureed food suitable for infant or toddler consumption), chips, cookies, breads, spreads, creams, yogurts, liquid drinks, chocolate containing products, candies, ice creams, cereals, coffees, pureed food products, etc.
- This example describes the selection of allergenic food ingredients for inclusion in an exemplary dry powder mixed allergen product containing 16 individual complete food allergens (almond, cashew, hazelnut, peanut, pecan, pistachio, walnut, sesame, soy, egg, milk, oat, wheat, cod, salmon, and shrimp).
- TABLE 1 shows a sample formulation for a mixed allergen product and representative pre-weighed batch amounts of individual complete food allergens provided for blending and sterilization.
- This example describes an exemplary blending process for the preparation of a mixed allergen product comprising 16 individual complete food allergens (almond, cashew, hazelnut, peanut, pecan, pistachio, walnut, sesame, soy, egg, milk, oat, wheat, cod, salmon, and shrimp).
- a 1,000 kg ribbon blender (Prince Industries, India) was cleaned, sanitized, and tested for adenosine triphosphate (ATP) and allergens. Actual batch amounts (in kg) of 16 individual complete food allergens as indicated in Table 1 were loaded into the ribbon blender and blended at 30 Hz for 15 minutes.
- ATP adenosine triphosphate
- This example describes an alternative blending and milling process for the preparation of a mixed allergen product comprising 16 individual complete food allergens (almond, cashew, hazelnut, peanut, pecan, pistachio, walnut, sesame, soy, egg, milk, oat, wheat, cod, salmon, and shrimp).
- a preliminary test for heat sensitivity was conducted to determine the suitability of the bulk mixed allergen material for sterilization treatment.
- This example describes an exemplary dry heat sterilization process that can be used for the preparation of a mixed allergen product comprising 16 individual food allergens (almond, cashew, hazelnut, peanut, pecan, pistachio, walnut, sesame, soy, egg, milk, oat, wheat, cod, salmon, and shrimp).
- a dry heat sterilization method similar to that which is contemplated in the present disclosure is described in US 2014/0023757, which is herein incorporated by reference.
- Bulk mixed allergen material blended as described in Examples 2 or 3, can be bagged in thermoresistant packaging.
- the bagged bulk mixed allergen material can then be placed in an insulated heat treatment chamber, wherein heat is supplied to the treatment chamber by multiple natural gas fired furnaces. Heat can be circulated through the insulated treatment chamber using multiple intake and exhaust ducts to facilitate uniform absorption of heat by the bagged bulk mixed allergen material.
- 6 bags of bulk mixed allergen material each weighing about 25 lbs./12 kg can be placed as a single layer on a pallet, and 14 pallets can be loaded into a heating chamber having dimensions of 40 feet long, 10 feet high, and 9 feet wide.
- the heating chamber can then be sealed, and the chamber can be heated to reach the target temperature of 74° C. Warm-up time for the chamber to reach the target temperature may take up to about 24 hours.
- the temperature of the heating chamber can be monitored using six probes within the heating chamber. For example, two probes may be placed in the back of the heating chamber, two probes may be place in the middle of the heating chamber, and two probes may be placed at the front of the heating chamber.
- the heating chamber can be maintained for a period of 24 hours.
- Temperatures of the insulated treatment chamber, multiple natural gas fired furnaces, and bagged bulk mixed allergen material can be monitored to ensure that the bulk mixed allergen material is applied with dry heat sterilization at a temperature of about 65° C. to about 175° C. for a period of 24 hours.
- the sterilized mixed allergen product can be unloaded from the heating chamber. Water activity, moisture level, and total plate counts can be measured for samples of the sterilized mixed allergen product and compared to samples of the bulk mixed allergen material prior to dry heat sterilization.
- samples can be diluted and spread onto petri dishes of general recovery media to measure colony-forming units per gram of product or material (CFU/g) for total aerobic microorganism and Enterobacteriaceae counts.
- CFU/g colony-forming units per gram of product or material
- E. coli /coliform, and S. aureus counts can be determined by diluting samples and spreading onto 3M PetrifilmTM E. coli /coliform and 3M PetrifilmTM Staph Express count plates, respectively, in accordance with the manufacturer's instructions (3M, St. Paul, Minnesota).
- Samples can be additionally tested for the presence of Listeria and Salmonella using the BAX® PCR detection system (Hygiena, Camarillo, California) in accordance with the manufacturer's instructions.
- Total mold and yeast counts can also be determined by diluting samples and spreading onto 3M PetrifilmTM mold and yeast count plates in accordance with the manufacturer's instructions.
- This example describes the validation of a dry heat process for sterilization of bulk mixed allergen material.
- SurroNov® 1830 a strain derived from Enterococcus Faecium ATCC®8459, was used as a surrogate microorganism to evaluate the lethality of the dry heat sterilization on Salmonella and Cronobacter pathogens.
- SurroNov® 1830 has a thermal resistance similar to, or greater than, the thermal resistance of Salmonella and Cronobacter .
- Validation was aimed at achieving at least a 5-log reduction in the number of viable SurroNov® 1830 organisms. Two validation trials were performed to evaluate variability.
- thermoresistant bags each containing 25 g of bulk mixed allergen material blended as described in Examples 2 or 3, were inoculated with approximately 1.4 ⁇ 10 6 SurroNov®1830 organisms. Each inoculated thermoresistant bag was placed into a box.
- Temperature of the heating chamber was monitored throughout the validation run using heat chamber probes: two positioned at the front of the heating chamber, two positioned in the middle of the heating chamber, and two positioned at the back of the heating chamber. Additionally, MadgeTech probes were included to monitor temperature of the heating chamber during the dry heat sterilization process. MadgeTech probes were either placed inside select inoculated thermoresistant bags of bulk mixed allergen material or outside the boxes.
- the temperature recorded by the MadgeTech probes are relatively homogeneous at different positions inside the chamber. Temperatures recorded by the heat chamber probes differ depending on the position inside the chamber (i.e. back, middle, or front), but temperatures between two probes in the same position are relatively similar during the dry heat sterilization treatment.
- the dry heat treatment was initially set to 175° F./80° C. It took 18 hours for all probes to reach the target temperature. Once the target temperature was attained, the temperature was decreased to 165° F./74° F. and maintained at this temperature for an additional 24 hours.
- the dry heat treatment was set to 165° F./74° C. It took 17 hours for all probes to reach the target temperature. Once the target temperature was attained, the dry heat sterilization temperature was maintained at 165° F./74° C. for an additional 24 hours.
- water activity and moisture content of sterilized mixed allergen product after validation trial 1 dry heat sterilization is lower than the water activity and moisture content of bulk mixed allergen material before dry heat treatment.
- Total plate counts on selective media were similar for bulk mixed allergen material before dry heat sterilization and mixed allergen product after dry heat sterilization.
- water activity of sterilized mixed allergen product after validation trial 2 dry heat sterilization is similar to the water activity of bulk mixed allergen material before dry heat treatment. Moisture content and total plate counts were lower following dry heat sterilization treatment in validation trial 2, as compared to bulk mixed allergen material that was not dry heat sterilized.
- dry heat sterilization in validation trial 2 resulted in greater than 5 log reductions in SurroNov® 1830 CFU/g in all samples, as compared to inoculated bulk mixed allergen material samples that were not dry heat treated.
- Particle size distribution can be measured for mixed allergen product samples treated with dry heat sterilization and compared to the particles of corresponding bulk mixed allergen material that did not receive application of dry heat sterilization.
- Samples can be filtered for 3 minutes using a Ro-Tap® sieve shaker and a series of mesh sizes consisting of #10, #12, #14, #16, #18, #20, #25, #30, #35, #40, and #50 meshes. Filtered particles and particles retained by each mesh can be individually removed, weighed, and distributions plotted as % weight versus particle size (in m).
- Protein integrity of mixed allergen product samples treated with dry heat sterilization can be compared to bulk mixed allergen material that did not receive application of dry heat sterilization. Protein integrity can be assessed by resolving all proteins present in non-sterilized and dry heat-sterilized samples by SDS-PAGE.
- 1 mg of bulk mixed allergen material or dry heat sterilized mixed allergen product can be weighed into 2 mL microtubes. Based on their assessed protein concentrations, samples can be diluted with Laemmli buffer containing 5% 2-mercaptoethanol (BioRad, Hercules, California) to a protein concentration of 1 mg/ml. Protein suspensions can be mixed by gentle inversion or intermittent vortexing for 5 minutes then heated to 95° C. to 100° C. for 5 minutes.
- Samples can be centrifuged for 1 minute at 1,000 RPM, then 10 ⁇ l of each sample can be loaded per well, in triplicate, on a 4-20% polyacrylamide gradient gel (BioRad, Hercules, California) immersed in 1 ⁇ SDS-PAGE running buffer (BioRad, Hercules, California). Gels can be run at 100 V for 80-90 minutes (or 200V for 30-40 minutes). Gels can then be washed 3 times with distilled water, 5 minutes per wash, on an orbital shaker at room temperature. Gels can be fixed in fixing solution (Sigma-Aldrich, St. Louis, Missouri) or 50% methanol, 10% acetic acid, for 15 minutes.
- Gels can be stained with EX Blue gel staining reagent (Sigma-Aldrich, St. Louis, Missouri) for 2 hours or overnight, then de-stained by washing in distilled water for 1-2 hours or overnight. Upon completion of washing, gels can be covered with clear plastic and scanned using a gel reader. Protein band densitometry can be analyzed using ImageJ public domain software (NIH, Bethesda, Maryland).
- the visual and organoleptic characteristics of mixed allergen product samples treated with dry heat sterilization can be compared to bulk mixed allergen material that did not receive application of dry heat sterilization.
- a comparison of taste profiles of dry heat sterilized mixed allergen product and non-sterilized bulk mixed allergen can also be performed.
Abstract
Methods of making mixed allergen products are provided, wherein the mixed allergen products are substantially free of replication viable organisms.
Description
- This application claims the benefit of and priority to U.S. Provisional Patent Application No. 62/795,877, filed Jan. 23, 2019, and to U.S. Provisional Patent Application No. 62/865,473, filed Jun. 24, 2019, the disclosure of which is hereby incorporated by reference in its entirety for all purposes.
- Allergy is a disorder of the immune system characterized by the occurrence of allergic reactions to normally harmless environmental substances. Allergies are caused by allergens, which may be present in a wide variety of sources including, but not limited to, pollens or other plant components, dust, molds or fungi, foods, additives, latex, transfusions, animal or bird danders, insect venoms, radiocontrast medium, medications, or chemicals. Common allergic reactions include eczema, hives, hay fever, asthma, and reactions to venoms. Mild allergies, like hay fever, are highly prevalent in the human population and cause symptoms such as allergic conjunctivitis, itchiness, and runny nose. In some people, severe allergies to environmental allergens, dietary allergens, or medication may result in life-threatening anaphylactic reactions if left untreated.
- A food allergy is an adverse immune response to a food allergen, for example, a food protein. Common food allergens are found in shellfish, peanuts, tree nuts, fish, milk, eggs, soy and fresh fruits such as strawberries, mangoes, bananas, and apples. Immunoglobulin E (IgE)-mediated food allergies are classified as type-I immediate hypersensitivity reactions. These allergic reactions have an acute onset (from seconds to one hour) and the accompanying symptoms may include: angioedema (soft tissue swelling of the eyelids, face, lips, tongue, larynx and trachea); hives; itching of the mouth, throat, eyes, and skin; gastrointestinal symptoms such as nausea, vomiting, diarrhea, stomach cramps, and abdominal pain; rhinorrhea or nasal congestion; wheezing; shortness of breath; difficulty swallowing; and anaphylaxis, a severe, whole-body allergic reaction that can result in death. It is estimated that 1 out of 12 children under 21 years of age have a diagnosed food allergy, and over $24 billion is spent per year on health care costs for food allergic reactions, largely due to about 90,000 emergency room visits per year in the U.S. alone due to food-induced anaphylaxis. Moreover, deaths occur every year due to fatal food allergies.
- Accordingly, there exists a need in the art for allergen compositions that can prevent and/or treat allergies, and methods for making allergen compositions to prevent and/or treat allergies.
- This disclosure is directed, at least in part, to a method of making a mixed allergen product substantially free of replication viable organisms. For example, in certain embodiments, the method comprises: providing bulk mixed allergen material comprising 2 to 20 individual complete food allergens; and sterilizing the bulk mixed allergen material by dry heat sterilization, thereby obtaining the mixed allergen product.
- In certain embodiments, a method further comprises providing 2 to 20 individual complete food allergens and blending the 2 to 20 individual complete food allergens together to obtain the bulk mixed allergen material.
- In other embodiments, the disclosure provides a method, wherein the 2 to 20 individual complete food allergens are selected from the group consisting of almond, cashew, cod, egg, hazelnut, milk, oat, peanut, pecan, pistachio, salmon, sesame, shrimp, soy, walnut, and wheat.
- In another embodiment, the disclosure provides a method, wherein the blending further comprises blending the 2 to 20 individual complete food allergens with one or more than one bulking agent.
- In certain embodiments of the present disclosure, blending comprises loading 2 to 20 individual complete food allergens into a ribbon blender set at about 10 Hz to about 50 Hz for about 10 minutes to about 50 minutes. In other embodiments, the bulk mixed allergen material is discharged into lined drums after blending.
- In certain embodiments, a method of the present disclosure further comprises filtering the mixed allergen product. In some embodiments, filtering comprises passing the mixed allergen product through a screen ranging from a #5 mesh (US) screen to a #10 mesh (US) screen on a shaker for about 1 minute to about 10 minutes.
- In some embodiments, a method of the present disclosure further comprises passing the mixed allergen product through a rare earth magnet, metal detector, and metal separator.
- In certain embodiments, a described method of the present disclosure provides applying dry heat sterilization, wherein the dry heat sterilization is at a temperature of about 65° C. to about 175° C. for about 18 hours to about 72 hours. In some embodiments, the dry heat sterilization comprises using a sterilization system having a furnace and a heating chamber, wherein the furnace provides about 250,000 BTUs to about 750,000 BTUs of heat to the heating chamber. In certain embodiments, the bulk mixed allergen material is first packaged into thermoresistant packaging before dry heat sterilization. In certain embodiments, temperature probes are placed with the bulk mixed allergen material during sterilizing to monitor the temperature of the dry heat sterilization.
- In certain embodiments of the present disclosure, the mixed allergen product has at least about a 1 log reduction to at least about a 4 log reduction in aerobic bacterial organism plate counts as compared to corresponding bulk mixed allergen material that has not been sterilized. In some embodiments, the mixed allergen product has less than about 10,000 CFU/g of aerobic bacterial organisms. In other embodiments, the mixed allergen product has less than about 10 CFU/g of coliforms, Escherichia coli, Enterobacteriaceae, mold, Staphylococcus aureus, and yeast. In certain embodiments, the mixed allergen product has less than about 10 CFU/g of Salmonella. In certain embodiments, the mixed allergen product has less than about 10 CFU/g of Cronobacter. In further embodiments, the mixed allergen product is negative in PCR-based assays for Listeria species, Cronobacter species and Salmonella species per 25 g of mixed allergen product, 25 g of mixed allergen product, and 375 g of mixed allergen product, respectively.
- In some embodiments of the present disclosure, the mixed allergen product has a fat content of about 10% to about 20% by weight.
- In other embodiments, protein integrity of the mixed allergen product is substantially similar to protein integrity of corresponding bulk mixed allergen material that has not been sterilized. In some embodiments, the protein integrity of the mixed allergen product is determined by SDS-PAGE.
- In certain embodiments, the mixed allergen product has a protein content of about 40% to about 50% by weight.
- In certain embodiments, the mixed allergen product has about 1% to about 10% moisture by weight. In other embodiments, the mixed allergen product has a water activity of about 0.1 to about 0.6.
- In certain embodiments of the present disclosure, the mixed allergen product comprises less than about 10% by weight of particles having a diameter greater than 500 m.
- In some embodiments, the mixed allergen product is darker in color as compared to corresponding bulk mixed allergen material that has not been sterilized. In other embodiments, the mixed allergen product has a substantially similar taste profile as compared to corresponding bulk mixed allergen material that has not been sterilized.
- In certain embodiments, a described method of the present disclosure comprises one or more than one further application of dry heat sterilization.
- In an alternative embodiment, the present disclosure describes a method of making a mixed allergen product substantially free of replication viable organisms, comprising: providing 2 to 20 individual complete food allergens; sterilizing each of the 2 to 20 individual complete food allergens by dry heat sterilization, thereby obtaining 2 to 20 sterilized individual complete food allergens; and blending the 2 to 20 sterilized individual complete food allergens together, thereby obtaining the mixed allergen product.
- In another embodiment, the present disclosure describes a method of making a mixed allergen product substantially free of replication viable organisms, wherein the method further comprises blending the mixed allergen product with one or more than one probiotic selected from the group consisting of Lactobacillus rhamnosus, Anaerostipes caccae, and Bifidobactierium longum.
- In yet another embodiment, the mixed allergen product is further blended with one or more than one prebiotic, for example, wherein the prebiotic is fructooligosaccharide.
- Also disclosed is a mixed allergen product substantially free of replication viable organisms prepared by any one of the methods disclosed herein.
-
FIG. 1 is a macroscopic image of non-sterilized bulk mixed allergen material sample and bulk mixed allergen material samples which have been heated in a laboratory oven for 5 minutes at 95° C., 105° C., 110° C., or 120° C. -
FIG. 2A is a schematic showing the placement of pallets and sample boxes containing thermoresistant bags of bulk mixed allergen material in a dry heat sterilization chamber forvalidation trial 1. B3 ofpallets pallets pallet 11 has a chamber probe placed inside the box.FIG. 2B is a schematic showing the placement of pallets and sample boxes containing thermoresistant bags of bulk mixed allergen material in a dry heat sterilization chamber forvalidation trial 2. B3 ofpallets pallets pallets -
FIG. 3A is line graph showing the temperature profile of the dry heat sterilization chamber duringvalidation trial 1.FIG. 3B is line graph showing the temperature profile of the dry heat sterilization chamber duringvalidation trial 2. Each line represents the temperature readings of a single chamber probe or MadgeTech probe. - Disclosed herein are methods of making a mixed allergen product substantially free of replication viable organisms.
- By “replication viable organisms”, it is meant organisms that are capable of multiplying, reproducing, propagating, and/or producing colony forming units (CFU) on a plate culture.
- By “sterilization”, it is meant a process that is capable of substantially reducing the number of replication viable organisms.
- As used herein, an “individual complete food allergen” refers to a food substance containing all possible antigenic components for said food substance (for example, allergenic proteins). Individual complete food allergens may include, but are not limited to, unprocessed or processed food substances, concentrated food substances, and isolated food substances.
- “Allergenic proteins”, as used herein, are antigenic components of food allergens that are, either directly or indirectly, responsible for eliciting a biological allergic response. Allergenic proteins may include, but are not limited to, nut proteins such as hazelnut proteins (e.g., Cor a 1, Cor a 2, Cor a 6, Cor a 8, Cor a 9, Cor a 10, Cor a 11, Cor a 12, Cor a 13, and Cor a 14), cashew proteins (e.g., Ana o 1, Ana o 2, and Ana o 3), pistachio proteins (e.g., Pis v 1, Pis v 2, Pis v 3, Pis v 4, and Pis v 5), walnut proteins (e.g., Jug r 1, Jug r 2, Jug r 3, Jug r 4, Jug r 5, Jug r 6, Jug r 7, and Jug r 8, Jug n1, Jug n 2, and Jug n 4), pecan proteins (e.g., Car i 1, Car i 2, and Car i 4), almond proteins (e.g., Pru du 3, Pru du 4, Pru du 5, Pru du 6, and Pru du 8), peanut proteins (e.g., Ara h 1, Ara h 2, Ara h 3, Ara h 4, Ara h 5, Ara h 6, Ara h 7, Ara h 8, Ara h 9, Ara h 10, Ara h 11, Ara h 12, Ara h 13, Ara h 14, Ara h 15, Ara h 16, and Ara h 17), and brazil nut proteins (e.g., Ber e 1 and Ber e 2). Allergenic proteins may also include, but are not limited to, animal proteins such as egg proteins (e.g., Gal d 1, Gal d 2, Gal d 3, Gal d 4, Gal d 5, Gal d 6, Gal d 7, Gal d 8, Gal d 9, Gal d 10), milk proteins (e.g., Bos d 2, Bos d 3, Bos d 4, Bos d 5, Bos d, 6, Bos d 7, Bos d 8, Bos d 9, Bos d 10, Bos d 11, and Bos d 12), salmon proteins (e.g., Onc k 5, Sal s 1, Sal s 2, and Sal s 3), cod proteins (e.g., pGad c 1, Gad m 1, Gad m 2, and Gad m 3), shrimp proteins (e.g., Cra c 1, Cra c 2, Cra c 4, Cra c 5, Cra c 6, Cra c 8, Lit v 1, Lit v 2, Lig v 3, Lit v 4, Met e 1, Pan b 1, Pen a 1, Pen i 1, Pen m 1, Pen m 2, Pen m 3, Pen m 4, and Pen m 6), and crab proteins (e.g., Cha f 1, Por p1, Scy p 2, Scy p 4, and Scy p 8). Allergenic proteins may further include, but are not limited to, non-nut plant proteins such as wheat proteins (e.g., Tri a 12, Tri a 14, Tri a 15, Tri a 17, Tri a 18, Tri a 19, Tri a 20, Tri a 21, Tri a 25, Tri a 26, Tri a 27, Tri a 28, Tri a 29, Tri a 30, Tri a 31, Tri a 32, Tri a 33, Tri a 34, Tri a 35, Tri a 36, Tri a 37, Tri a 39, Tri a 40, Tri a 41, Tri a 42, Tri a 43, Tri a 44, and Tri a 45), soy proteins (e.g., Gly m 1, Gly m 1.0101, Gly m 2, Gly m 3, Gly m 4, Gly m 5, Gly m 6, Gly m 7, and Gly m 8), chickpea proteins, sesame seed proteins (e.g., Ses i 1, Ses i 2, Ses i 3, Ses i 4, Ses i 5, Ses i 6, and Ses i 7), kiwi proteins (e.g., Act c 1, Act c 5, Act c 8, Act c 10, Act d 1, Act d 2, Act d 3, Act d 4, Act d 5, Act d 6, Act d 7, Act d 8, Act d 9, Act d 10, Act d 11, Act d 12, and Act d 13), carrot proteins (e.g., Dau c 1, Dau c4, and Dau c5), celery proteins (e.g., Api q 1, Api q 2, Api q 3, Api q 4, Api q 5, and Api q 6), stone fruit proteins (e.g., Pru ar 1, Pru ar 3, Pru av 1, Pru av 2, Pru av 3, Pru av 4, Pru p 1, Pru p 2, Pru p 3, Pru p4, Pru p 7, and Pru d 3), and oat proteins.
- Presently disclosed, for example, is a method of making a mixed allergen product substantially free of replication viable organisms, comprising: providing bulk mixed allergen material comprising 2 to 20 individual complete food allergens; and sterilizing the bulk mixed allergen material by dry heat sterilization, thereby obtaining the mixed allergen product.
- In certain embodiments, bulk mixed allergen material comprises 2 to 20 individual complete food allergens, for example, 4 to 20, 6 to 20, 8 to 20, 10 to 20, 12 to 20, 14 to 20, 16 to 20, 18 to 20, 2 to 18, 4 to 18, 6 to 18, 8 to 18, 10 to 18, 12 to 18, 14 to 18, 16 to 18, 2 to 16, 4 to 16, 6 to 16, 8 to 16, 10 to 16, 12 to 16, or 14 to 16 individual complete food allergens. For example, bulk mixed allergen material may comprise 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 individual complete food allergens. In a particular embodiment, bulk mixed allergen material comprises 15 or 16 individual complete food allergens.
- For example, in certain embodiments, the individual complete food allergens are selected from the group consisting of nut, seed, legume, egg, dairy, fish and crustacean. In particular embodiments, the individual complete food allergens are selected from the group consisting of almond, cashew, hazelnut, peanut, pecan, pistachio, walnut, sesame, soy, egg, milk, oat, wheat, cod, salmon, and shrimp. In certain embodiments, the individual complete food allergens are almond, cashew, hazelnut, peanut, pecan, pistachio, walnut, sesame, soy, egg, milk, oat, wheat, cod, salmon, and shrimp. It is contemplated that the individual complete food allergens may be provided as a meal, flour, powder, and/or protein concentrate.
- In certain embodiments, a described method further comprises providing 2 to 20 individual complete food allergens, and blending the 2 to 20 individual complete food allergens together to obtain bulk mixed allergen material. It will be appreciated that two or more individual complete food allergens may be provided in combination prior to blending. For example, 2 to 20, 4 to 20, 6 to 20, 8 to 20, 10 to 20, 12 to 20, 14 to 20, 16 to 20, 18 to 20, 2 to 18, 4 to 18, 6 to 18, 8 to 18, 10 to 18, 12 to 18, 14 to 18, 16 to 18, 2 to 16, 4 to 16, 6 to 16, 8 to 16, 10 to 16, 12 to 16, or 14 to 16 individual complete food allergens may be provided in combination prior to blending. In a further example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 individual complete food allergens may be provided in combination prior to blending.
- It will be appreciated that blending may comprise one or more than one blending steps to obtain bulk mixed allergen material. For example, individual complete food allergens may be blended in 1 to 19, 1 to 17, 1 to 15, 1 to 13, 1 to 11, 1 to 9, 1 to 7, 1 to 5, or 1 to 3 blending steps. In a particular embodiment, blending comprises mixing individual complete food allergens in a single blending step.
- As contemplated in the present disclosure, bulk mixed allergen material is sterilized by dry heat sterilization. It will be appreciated that sterilizing may further comprise one or more than one additional application of dry heat sterilization, to inactivate heat-resistant spores.
- In certain embodiments, dry heat may be supplied to a treatment chamber of a sterilization system within which bulk mixed allergen material is held or is conveyed, wherein the treatment chamber may be heated to a temperature of about 65° C. to about 175° C. For example, in certain embodiments, the treatment chamber may be heated to about 65° C. to about 80° C., about 65° C. to about 120° C., about 100° C. to about 150° C., or about 125° C. to about 175° C. In particular embodiments, the treatment chamber may be heated to a temperature of about 65° C., about 66° C., about 67° C., about 68° C., about 69° C., about 70° C., about 71° C., about 72° C., about 73° C., about 74° C., about 75° C., about 85° C., about 95° C., about 105° C., about 115° C., about 125° C., about 135° C., about 145° C., about 155° C., about 165° C., or about 175° C. In further embodiments, dry heat may be applied to bulk mixed allergen material for about 3 minutes to about 72 hours. In certain embodiments, for example, dry heat may be applied for about 3 minutes to about 72 hours, about 30 minutes to about 72 hours, about 12 hours to about 72 hours, about 18 hours to about 72 hours, about 24 hours to about 72 hours, about 30 hours to about 72 hours, about 36 hours to about 72 hours, about 42 hours to about 72 hours, about 48 hours to about 72 hours, about 54 hours to about 72 hours, about 60 hours to about 72 hours, or about 66 hours to about 72 hours. For example, in particular examples, dry heat may be applied to bulk mixed allergen material for about 30 minutes, about 45 minutes, about 60 minutes, about 75 minutes, about 90 minutes, about 105 minutes, about 120 minutes, about 12 hours, about 18 hours, about 24 hours, about 30 hours, about 36 hours, about 42 hours, about 48 hours, about 54 hours, about 60 hours, about 66 hours, or about 72 hours.
- In certain embodiments, for example, dry heat may be provided to a treatment chamber of a sterilization system by multiple natural gas fired furnaces that provide about 250,000 BTUs to about 750,000 BTUs of heat to the treatment chamber. For example, about 250,000 BTUs, about 300,000 BTUs, about 350,000 BTUs, about 400,000 BTUs, about 450,000 BTUs, about 500,000 BTUs, about 550,000 BTUs, about 600,000 BTUs, about 650,000 BTUs, about 700,000 BTUs, or about 750,000 BTUs of heat may be provided to the treatment chamber.
- In a further embodiment, dry heat sterilization may be applied to bulk mixed allergen material packaged in thermoresistant packaging. As used herein, “thermoresistant” is understood to mean that applying the same temperature and duration of heat to the packaging material as concurrently applied to the bulk mixed allergen material packaged therein, does not cause changes in the packaging material that affect its integrity and functionality as a barrier to chemical or microbial contamination. Furthermore, “thermoresistant” is understood to mean that applying the same temperature and duration of heat to the packaging material as concurrently applied to the bulk mixed allergen material packaged therein, does not alter the packaging to cause a chemical in the packaging to be added to the bulk mixed allergen material packaged therein. For example, the thermoresistant packaging may include, but is not limited to, bulk bags, pouches, or stickpacks. In a further example, the thermoresistant packaging may be placed in boxes and/or on pallets or racks within a heating chamber for dry heat sterilization.
- As contemplated in a described method of the present disclosure, blending may comprise loading 2 to 20 individual complete food allergens (e.g., 4 to 20, 6 to 20, 8 to 20, 10 to 20, 12 to 20, 14 to 20, 16 to 20, 18 to 20, 2 to 18, 4 to 18, 6 to 18, 8 to 18, 10 to 18, 12 to 18, 14 to 18, 16 to 18, 2 to 16, 4 to 16, 6 to 16, 8 to 16, 10 to 16, 12 to 16, or 14 to 16 individual complete food allergens) into a mechanical blender or mixer. For example, the mechanical blender or mixer may be selected from, but not limited to: a ribbon blender; a paddle blender; a plow blender; a fluidizing blender; an intensive mixer; a vacuum mixer; a conical mixer; a rotary batch mixer; and a double shaft mixer. In a particular embodiment, the individual complete food allergens are loaded into a ribbon blender. Without wishing to be bound by theory, it is believed that blending by loading the individual complete food allergens into a mechanical blender or mixer reduces grittiness, reduces the number of large particles, and increases homogeneity.
- It will be appreciated that each individual complete food allergen may be loaded into the mechanical blender or mixer in various amounts including, for example, but not limited to: about 5 kg to about 100 kg; about 10 kg to about 90 kg; about 15 kg to about 80 kg; about 20 kg to about 70 kg; about 25 kg to about 60 kg; and about 30 kg to about 50 kg. It will be further appreciated that the mechanical blender or mixer may accommodate various total combined amounts of complete food allergens. In certain embodiments, for example, the mechanical blender or mixer may accommodate a total combined amount of complete food allergens of about 100 kg to about 2200 kg or about 500 kg to about 2000 kg. For example, in some embodiments the mechanical blender or mixer may accommodate an amount of about 500 kg, about 600 kg, about 700 kg, about 800 kg, about 900 kg, about 1000 kg, about 1100 kg, about 1200 kg, about 1500 kg, about 1600 kg, about 1700 kg, about 1800 kg, about 1900 kg, or about 2000 kg of total combined complete food allergens.
- It will also be appreciated that the settings of the mechanical blender or mixer may be adjusted so as to achieve optimal blending and/or mixing of the individual complete food allergens. For example, the mechanical blender may be set to about 10 Hz to about 50 Hz (e.g., about 15 Hz to about 45 Hz, about 20 Hz to about 40 Hz, or about 25 Hz to about 35 Hz). The mechanical blender may also be set to operate for various lengths of time. For example, the mechanical blender may blend the individual food allergens for about 5 minutes to about 30 minutes, about 7.5 minutes to about 25 minutes, or about 10 minutes to about 20 minutes. In a particular embodiment, the mechanical blender or mixer is a 1000 kg capacity ribbon blender and blends the individual complete food allergens at 30 Hz for 15 minutes.
- In certain embodiments, a method of the present disclosure further comprises blending the 2 to 20 individual complete food allergens with one or more than one bulking agents. Contemplated bulking agents may include any bulking agent described herein. In certain embodiments, the bulking agent comprises a sugar, for example, sucrose, maltodextrin, trehalose, trehalose dihydrate, isomalt, mannitol, lactose, dextrose, fructose, raffinose, or any combination thereof. In certain embodiments, the bulking agent comprises maltodextrin, or sucrose, or a combination thereof.
- In certain embodiments, bulk mixed allergen material may be discharged from a mechanical blender or mixer into lined drums before being loaded for sterilization. In further embodiments, the bulk mixed allergen material discharged into lined drums may be packaged in bags or pouches.
- Also contemplated is a method of making a mixed allergen product, further comprising filtering a mixed allergen product to remove agglomerate particles. For example, a mixed allergen product may be filtered through a screen ranging from a #5 mesh (US) screen to a #10 mesh (US) screen on a shaker for about 1 minute to about 10 minutes. For example, the screen may be a #5 mesh (US) screen, a #6 mesh (US) screen, a #7 mesh (US) screen, a #8 mesh (US) screen, a #9 mesh (US) screen, or a #10 mesh (US) screen. In a particular embodiment, the mixed allergen product is filtered through a screen ranging from a #5 mesh (US) screen to a #10 mesh (US) screen on a shaker for about 3 minutes.
- In certain embodiments, a method of making a mixed allergen product may further comprise magnetically sifting a mixed allergen product to remove metallic particles. For example, magnetic sifting may comprise passing mixed allergen product through a rare earth magnet, a metal detector, and/or a metal separator. In a further example, the metal detector may detect stainless steel particles at least about 2 mm to about 2.5 mm in size, ferrous particles at least about 1.5 mm to about 2 mm in size, and non-ferrous particles with a sensitivity of about 1.5 to 2 parts per million.
- In further embodiments, a method of making a mixed allergen product may be a continuous process, wherein the total completion time for the method is about 3 minutes to about 72 hours, about 30 minutes to about 72 hours, about 12 hours to about 72 hours, about 18 hours to about 72 hours, about 24 hours to about 72 hours, about 30 hours to about 72 hours, about 36 hours to about 72 hours, about 42 hours to about 72 hours, about 48 hours to about 72 hours, about 54 hours to about 72 hours, about 60 hours to about 72 hours, or about 66 hours to about 72 hours. For example, in particular examples, the total completion time for the method is about 30 minutes, about 45 minutes, about 60 minutes, about 75 minutes, about 90 minutes, about 105 minutes, about 120 minutes, about 12 hours, about 18 hours, about 24 hours, about 30 hours, about 36 hours, about 42 hours, about 48 hours, about 54 hours, about 60 hours, about 66 hours, or about 72 hours.
- In methods of the present disclosure, sterilizing bulk mixed allergen material by dry heat sterilization, produces a mixed allergen product that is substantially free of replication viable organisms.
- In certain embodiments, a mixed allergen product of the present disclosure is substantially free of replication viable bacteria, yeast, and/or molds. In some embodiments, a mixed allergen product may have: at least about a 1 log reduction to at least about a 9 log reduction; at least about a 1 log reduction to about a 4 log reduction; at least about a 1 log reduction to about a 5 log reduction; at least about a 1 log reduction to about a 6 log reduction; at least about a 1 log reduction to about a 7 log reduction; at least about a 1 log reduction to about a 8 log reduction, or at least about a 3 log reduction to about a 9 log reduction in aerobic bacterial organism plate counts as compared to a corresponding bulk mixed allergen material that has not been sterilized. For example, a mixed allergen product may have at least about a 1 log reduction, at least about a 2 log reduction, at least about a 3 log reduction, at least about a 4 log reduction, at least about a 5 log reduction, at least about a 6 log reduction, at least about a 7 log reduction, at least about a 8 log reduction, or at least about a 9 log reduction. in aerobic bacterial organism plate counts as compared to a corresponding bulk mixed allergen material that has not been sterilized. In a further example, a mixed allergen product has less than about 100,000 CFU/g, 10,000 CFU/g, less than about 1,000 CFU/g, less than about 100 CFU/g, or less than about 10 CFU/g of aerobic bacterial organisms. In another example, a mixed allergen product has less than about 100 CFU/g, less than about 10 CFU/g, or less than about 1 CFU/g of coliforms. In yet another example, a mixed allergen product may have less than about 10 CFU/g of a pathogenic microbial strain. For example, a mixed allergen product has less than about 100 CFU/g, less than about 10 CFU/g, or less than about 1 CFU/g of Escherichia coli. In a further example, a mixed allergen product has less than about 100 CFU/g, less than about 10 CFU/g, or less than about 1 CFU/g of Enterobacteriaceae. In another example, a mixed allergen product has less than about 100 CFU/g, or less than about 10 CFU/g of Salmonella. In another example, a mixed allergen product has less than about 100 CFU/g, or less than about 10 CFU/g of Cronobacter. In yet another example, a mixed allergen product is negative for Listeria species or Cronobacter species per 25 g sample of said mixed allergen product as determined by a PCR-based assay. In another example, a mixed allergen product has less than about 100 CFU/g, less than about 10 CFU/g, or less than about 1 CFU/g of mold. In yet another example, a mixed allergen product is negative for Salmonella species per 375 g sample of said mixed allergen product as determined by a PCR-based assay. In a further example, a mixed allergen product has less than about 100 CFU/g, less than about 10 CFU/g, or less than about 1 CFU/g of Staphylococcus aureus. In another example, a mixed allergen product has less than about 100 CFU/g, less than about 10 CFU/g, or less than about 1 CFU/g of yeast.
- In certain embodiments, a mixed allergen product of the present disclosure has a fat content of at least about 5% by weight. For example, a mixed allergen product may have a fat content of about 10% to about 20% by weight. In some embodiments, for example, a mixed allergen product may have a fat content of about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, or about 20% by weight.
- It is contemplated that applying dry heat sterilization to bulk mixed allergen material will not substantially alter protein integrity. For example, in certain embodiments, a sterilized mixed allergen product has substantially the same protein integrity as a corresponding bulk mixed allergen material that has not been sterilized. In a further example, protein integrity is determined by SDS-PAGE, wherein mixed allergen product has substantially similar protein bands, protein band distribution, and protein band intensity as non-sterilized bulk mixed allergen material.
- It is further contemplated that applying dry heat sterilization to bulk mixed allergen material will not substantially affect the ability of bulk mixed allergen material to elicit an allergen effect upon being consumed by an individual. As used herein, “allergen effect” is understood to mean an immune reaction to one or more than one antigenic component characterized by, but not limited to, immune cell activation, production of cytokines, and production of IgE. In certain embodiments, mixed allergen product has a substantially similar allergen effect upon being consumed by an individual as consumption of a substantially similar protein amount of corresponding bulk mixed allergen material that has not been sterilized. In certain embodiments, an allergen effect is measured by the production of IgE or cytokines, or measuring immune cell activation in response to consumption of bulk mixed allergen material or mixed allergen product by an individual. In other embodiments, the allergen effect is measured by an in vitro immune response, for example, measuring the production of IgE or cytokines, or measuring activation of immune cell cultures following treatment with bulk mixed allergen material or mixed allergen product.
- In certain embodiments, a mixed allergen product of the present disclosure has a protein content of about 40% to about 50% by weight. For example, a mixed allergen product may have a protein content of about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, or about 50% by weight.
- In certain embodiments, a mixed allergen product of the present disclosure has about 1% to about 10% moisture by weight. For example, a mixed allergen product may have about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10% moisture by weight.
- In certain embodiments, a mixed allergen product of the present disclosure has about 0.1 to about 0.6 water activity. “Water activity” is understood as the ratio between the vapor pressure of the mixed allergen product and the vapor pressure of distilled water under identical conditions. It will be appreciated that water activity is a measure of the water that is not bound to the molecules of the mixed allergen product and thus capable of supporting growth of bacteria, yeast and mold. Furthermore, it will be appreciated that water activity may be measured using suitable electronic instruments such as moisture meters, moisture-humidity meters, hygrometers, and relative humidity systems.
- In certain embodiments, a mixed allergen product of the present disclosure has less than about 10% by weight of particles having a diameter greater than 500 μm.
- In yet another embodiment, a mixed allergen product of the present disclosure has a substantially similar taste profile as compared to corresponding bulk mixed allergen material that has not been sterilized. For example, a mixed allergen product may have one or more than one flavor selected from, but not limited to, savory, nutty, marine, roasted, and brown. In a further example, a mixed allergen product does not have any off-flavors from processing.
- In another embodiment, a method of making a mixed allergen product substantially free of replication viable organisms is contemplated, wherein 2 to 20 individual food allergens are sterilized by dry heat sterilization before blending to obtain a mixed allergen product.
- In certain embodiments, a method of making a mixed allergen product further comprises blending the mixed allergen product with one or more than one probiotic selected from a group including, but not limited to, Lactobacillus species, Bifidobacterium species, Anacaerostipes species, and Bacillus species. For example, one or more probiotic may be selected from a group including, but not limited to Lactobacillus rhamnosis, Anaerostipes caccae, Bifidobacterium longum, Bifidobacterium lactis, Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus brevis, Lactobacillus salivarius, Lactococcus lactis, Bacillus coagulans, Lactobacillus bulgaricus, Lactobacillus gasseri, Lactobacillus paracasei, Bacillus coagulans and Bifidobacterium bifidum. In a particular embodiment, a method of making a mixed allergen product further comprises blending the mixed allergen product with Lactobacillus rhamnosis and/or Bifidobacterium longum. As used herein, “probiotic” refers to a culture (pure or mixed), comprising microorganisms which, when ingested, beneficially affect the host.
- In other embodiments, a method of making a mixed allergen product further comprises blending the mixed allergen product with one or more than one prebiotic selected from a group including, but not limited to, fructooligosaccharide, inulin, isomalto-oligosaccharide, lactilol, lactosucrose, lactulose, pyrodextrin, soybean oligosaccharide, xylooligosaccharide, transgalactooligosaccharide, oligosaccharide, soluble corn fiber, beta-glucan, oligofructose, and bipolymer. In a particular embodiment, a method of making a mixed allergen product further comprises blending the mixed allergen product with fructooligosaccharide. The term “prebiotic”, as used herein, refers to a specific dietary food or nutrient that promotes the growth, proliferation, and/or activity of a specific, desirable, bacterial strain.
- A disclosed mixed allergen product may further include one or more vitamins, as desired. Vitamins that may be present include, for example, vitamin A (e.g., in an amount ranging from about 1 to about 35,000 IU), vitamin C (e.g., in an amount ranging from about 1 to about 1,000 mg), vitamin D (e.g., in an amount ranging from about 1 to about 4,000 IU, i.e. from about 0.025 to about 100 mcg), vitamin E (e.g., in an amount ranging from about 1 to about 450 IU), vitamin K (e.g., in an amount ranging from about 1 to about 250 μg), vitamin B-1 (thiamin; e.g., in amount ranging from about 1 to about 15 mg), vitamin B-2 (riboflavin; e.g., in an amount ranging from about 1 to about 17 mg), vitamin B-3 (niacin; e.g., in an amount ranging from about 1 to about 200 mg), vitamin B-5 (pantothenic acid; e.g., in an amount ranging from about 1 to about 100 mg), vitamin B-6 (pyridoxine; e.g., in an amount ranging from about 1 to about 30 mg), vitamin B-9 (folic acid; e.g., in an amount ranging from about 1 to about 4,000 μg), vitamin B-12 (cobalamin; e.g., in an amount ranging from about 1 to about 250 μg), vitamin H (biotin; e.g., in an amount ranging from about 1 to about 1,000 μg) and combinations thereof. In certain embodiments, a mixed allergen product comprises vitamin D. In certain embodiments, a mixed allergen product comprises 400 IU, i.e. about 10 μg, of vitamin D.
- Also contemplated is a method of making a mixed allergen product, wherein the mixed allergen product is further mixed with a physiologically acceptable delivery vehicle to produce a physiologically acceptable composition. Mixed allergen products can be further incorporated into a variety of formulations for administration to a subject. More particularly, a mixed allergen product can be formulated into a physiological acceptable composition by combination with appropriate, physiologically acceptable carriers or diluents, for example, a vegetable oil.
- In certain embodiments, a disclosed mixed allergen product is designed for oral immunotherapeutic treatment of food allergy in a child or adult, for example, as dispersible powders or granules, foods, tablets, troches, lozenges, gummies, emulsions, etc. Compositions intended for oral use may be prepared according to any convenient protocol for the manufacture of oral compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents (e.g., glycerol, propylene glycol, sorbitol, or sucrose), flavoring agents, coloring agents and preserving agents in order to provide palatable preparations.
- Also contemplated is a method of making a mixed allergen product, wherein the mixed allergen product is mixed or incorporated with food to which a child or adult is not allergic. For example, foods may include, but are not limited to: baby or infant formula, baby food (e.g., pureed food suitable for infant or toddler consumption), chips, cookies, breads, spreads, creams, yogurts, liquid drinks, chocolate containing products, candies, ice creams, cereals, coffees, pureed food products, etc.
- Throughout the description, where apparatus, devices, and systems are described as having, including, or comprising specific components, or where processes and methods are described as having, including, or comprising specific steps, it is contemplated that, additionally, there are apparatus, devices, and systems that consists essentially of, or consist of, the recited components, and that there are processes and methods that consist essentially of, or consist of, the recited processing steps.
- All examples presented herein are for illustrative purposes only, and should not be construed as limiting in any way.
- This example describes the selection of allergenic food ingredients for inclusion in an exemplary dry powder mixed allergen product containing 16 individual complete food allergens (almond, cashew, hazelnut, peanut, pecan, pistachio, walnut, sesame, soy, egg, milk, oat, wheat, cod, salmon, and shrimp).
- Ingredients were sourced with primary emphasis on domestic commercial availability, with exceptions made for individual complete food allergens that were only available internationally. Successful commercial sourcing of multiple options per each individual complete food allergen led to development of selection criteria in order to choose the best commercial food allergen to be tested. Attributes screened included: protein content; bulking material content; organoleptic attributes such as taste, presence of off-notes, and grittiness; and solubility. Ingredients having considerably low protein content, or having a large proportion of bulking materials were eliminated from contention. Individual complete food allergens were tasted dry to determine the presence of off-flavors and to assess grittiness.
- TABLE 1 shows a sample formulation for a mixed allergen product and representative pre-weighed batch amounts of individual complete food allergens provided for blending and sterilization.
-
TABLE 1 Individual Batch for Actual Complete Food Formulation Formulation Sterilization Batch Allergen (g) (%) Run (kg) (kg) Almond Powder, 0.6895 6.620 33.10 33.10 50% Cashew Powder, 0.10720 10.294 51.47 51.47 35% Cod Powder 0.02291 2.200 11.00 11.00 Whole Egg 0.06742 6.473 32.37 32.37 Powder Hazelnut Powder 0.08824 8.472 42.36 42.36 Milk Protein 0.03534 3.393 16.96 6.35 Isolate Oat Protein 0.06266 6.017 30.08 30.08 Peanut Powder 0.06122 5.879 29.39 29.39 Pecan Powder 0.09816 9.425 47.13 47.13 Pistachio Powder 0.08867 8.514 42.57 42.57 Salmon Protein 0.07560 7.259 36.30 36.30 Powder Sesame Seed 0.06100 5.857 29.28 29.28 Powder Shrimp Powder 0.04261 4.092 20.46 20.46 Soy Protein 0.03736 3.588 17.94 17.94 Isolate Walnut Powder 0.08316 7.985 39.93 39.93 Wheat Gluten 0.04096 3.933 19.67 19.67 Total 1.04146 100.00 500.00 489.39 - This example describes an exemplary blending process for the preparation of a mixed allergen product comprising 16 individual complete food allergens (almond, cashew, hazelnut, peanut, pecan, pistachio, walnut, sesame, soy, egg, milk, oat, wheat, cod, salmon, and shrimp).
- A 1,000 kg ribbon blender (Prince Industries, India) was cleaned, sanitized, and tested for adenosine triphosphate (ATP) and allergens. Actual batch amounts (in kg) of 16 individual complete food allergens as indicated in Table 1 were loaded into the ribbon blender and blended at 30 Hz for 15 minutes.
- Bulk mixed allergen material was discharged from the ribbon blender into lined drums (40 to 50 kg per drum).
- This example describes an alternative blending and milling process for the preparation of a mixed allergen product comprising 16 individual complete food allergens (almond, cashew, hazelnut, peanut, pecan, pistachio, walnut, sesame, soy, egg, milk, oat, wheat, cod, salmon, and shrimp).
- All individual complete food allergens were weighed to make 8 kg batches. Individual complete food allergens were transferred to a D500 Hobart mixer equipped with a D-30 Bowl and safety cage. Individual complete food allergens were mixed with a paddle attachment “B” flat beater on setting 1 for 2 minutes. Blended complete food allergens were transferred to large, food-grade, plastic bags, sealed, and stored at room temperature until milling. Blended complete food allergens were slowly fed into a Quadro SLS-L1A FitzMill equipped with a #20 mesh screen and set to 9,000 rpm to achieve a target particle size of <500 μm in diameter. Milled complete food allergens were passed through a metal detector and #35 mesh screen before packaging.
- A preliminary test for heat sensitivity was conducted to determine the suitability of the bulk mixed allergen material for sterilization treatment.
- Bulk mixed allergen material was placed in a pan and subjected to different temperatures in a laboratory oven for 5 minutes.
- As shown in
FIG. 1 , apart from a slight darkening in color with increased temperature, bulk mixed allergen material did not exhibit any other physical alterations with heat treatments of 95° C., 105° C., 110° C., or 120° C. for 5 minutes that would make the material unsuitable for sterilization treatment. - This example describes an exemplary dry heat sterilization process that can be used for the preparation of a mixed allergen product comprising 16 individual food allergens (almond, cashew, hazelnut, peanut, pecan, pistachio, walnut, sesame, soy, egg, milk, oat, wheat, cod, salmon, and shrimp). A dry heat sterilization method similar to that which is contemplated in the present disclosure is described in US 2014/0023757, which is herein incorporated by reference.
- Bulk mixed allergen material, blended as described in Examples 2 or 3, can be bagged in thermoresistant packaging. The bagged bulk mixed allergen material can then be placed in an insulated heat treatment chamber, wherein heat is supplied to the treatment chamber by multiple natural gas fired furnaces. Heat can be circulated through the insulated treatment chamber using multiple intake and exhaust ducts to facilitate uniform absorption of heat by the bagged bulk mixed allergen material.
- For example, 6 bags of bulk mixed allergen material, each weighing about 25 lbs./12 kg can be placed as a single layer on a pallet, and 14 pallets can be loaded into a heating chamber having dimensions of 40 feet long, 10 feet high, and 9 feet wide.
- The heating chamber can then be sealed, and the chamber can be heated to reach the target temperature of 74° C. Warm-up time for the chamber to reach the target temperature may take up to about 24 hours.
- The temperature of the heating chamber can be monitored using six probes within the heating chamber. For example, two probes may be placed in the back of the heating chamber, two probes may be place in the middle of the heating chamber, and two probes may be placed at the front of the heating chamber.
- Once the target temperature is reached, the heating chamber can be maintained for a period of 24 hours.
- Temperatures of the insulated treatment chamber, multiple natural gas fired furnaces, and bagged bulk mixed allergen material can be monitored to ensure that the bulk mixed allergen material is applied with dry heat sterilization at a temperature of about 65° C. to about 175° C. for a period of 24 hours.
- Following dry heat treatment, the sterilized mixed allergen product can be unloaded from the heating chamber. Water activity, moisture level, and total plate counts can be measured for samples of the sterilized mixed allergen product and compared to samples of the bulk mixed allergen material prior to dry heat sterilization.
- For example, samples can be diluted and spread onto petri dishes of general recovery media to measure colony-forming units per gram of product or material (CFU/g) for total aerobic microorganism and Enterobacteriaceae counts. E. coli/coliform, and S. aureus counts can be determined by diluting samples and spreading onto 3M Petrifilm™ E. coli/coliform and 3M Petrifilm™ Staph Express count plates, respectively, in accordance with the manufacturer's instructions (3M, St. Paul, Minnesota).
- Samples can be additionally tested for the presence of Listeria and Salmonella using the BAX® PCR detection system (Hygiena, Camarillo, California) in accordance with the manufacturer's instructions.
- Total mold and yeast counts can also be determined by diluting samples and spreading onto 3M Petrifilm™ mold and yeast count plates in accordance with the manufacturer's instructions.
- This example describes the validation of a dry heat process for sterilization of bulk mixed allergen material.
- In this dry heat process, SurroNov® 1830, a strain derived from Enterococcus Faecium ATCC®8459, was used as a surrogate microorganism to evaluate the lethality of the dry heat sterilization on Salmonella and Cronobacter pathogens. SurroNov® 1830 has a thermal resistance similar to, or greater than, the thermal resistance of Salmonella and Cronobacter. Validation was aimed at achieving at least a 5-log reduction in the number of viable SurroNov® 1830 organisms. Two validation trials were performed to evaluate variability.
- Before dry heat sterilization, 70 thermoresistant bags, each containing 25 g of bulk mixed allergen material blended as described in Examples 2 or 3, were inoculated with approximately 1.4×106 SurroNov®1830 organisms. Each inoculated thermoresistant bag was placed into a box.
- Six inoculated bags of bulk mixed allergen material were not introduced into the dry heat sterilization process and served as non-treated control samples.
- 14 pallets, each containing four boxes of inoculated thermoresistant bags of bulk mixed allergen material, were loaded into the heating chamber as shown in
FIGS. 2A and 2B forvalidation trials pallets boxes 3 and/or 4. - Temperature of the heating chamber was monitored throughout the validation run using heat chamber probes: two positioned at the front of the heating chamber, two positioned in the middle of the heating chamber, and two positioned at the back of the heating chamber. Additionally, MadgeTech probes were included to monitor temperature of the heating chamber during the dry heat sterilization process. MadgeTech probes were either placed inside select inoculated thermoresistant bags of bulk mixed allergen material or outside the boxes.
- As shown in
FIGS. 3A and 3B forvalidation trials - For validation trial 1 (
FIG. 3A ), the dry heat treatment was initially set to 175° F./80° C. It took 18 hours for all probes to reach the target temperature. Once the target temperature was attained, the temperature was decreased to 165° F./74° F. and maintained at this temperature for an additional 24 hours. - For validation trial 2 (
FIG. 3B ), the dry heat treatment was set to 165° F./74° C. It took 17 hours for all probes to reach the target temperature. Once the target temperature was attained, the dry heat sterilization temperature was maintained at 165° F./74° C. for an additional 24 hours. - As shown in TABLE 2, water activity and moisture content of sterilized mixed allergen product after
validation trial 1 dry heat sterilization is lower than the water activity and moisture content of bulk mixed allergen material before dry heat treatment. Total plate counts on selective media were similar for bulk mixed allergen material before dry heat sterilization and mixed allergen product after dry heat sterilization. -
TABLE 2 Water Activity Moisture Log Total Plate (aw) Content (%) Count Bulk Mixed Allergen 0.286 ± 0.002 1.63 ± 0.08 % 3.0 ± 0.3 log cfu/g Material (before dry heat sterilization) Mixed Allergen 0.235 ± 0.029 1.26 ± 0.21 % 2.8 ± 0.7 log cfu/g Product (after dry heat sterilization) - As shown in TABLE 3, bulk mixed allergen material samples that were not treated with dry heat sterilization had a mean SurroNov® 1830 count of 8.1±0.1 log cfu/g.
-
TABLE 3 Control Sample CFU/ g Log Mean 1 1.4 × 108 8.1 8.1 ± 0.1 2 1.5 × 108 8.2 3 1.5 × 108 8.2 4 1.2 × 108 8.1 5 1.3 × 108 8.1 6 1.5 × 108 8.2 - As shown in TABLE 4, greater than 5 log reductions in SurroNov® 1830 CFU/g was achieved in all samples following dry heat sterilization in
validation trial 1, as compared to inoculated bulk mixed allergen material samples that were not dry heat treated. -
TABLE 4 ID CFU/g Log Log Reduction PS7 <10 <1 >7.1 PS8 <10 <1 >7.1 PS9 <10 <1 >7.1 PS10 <10 <1 >7.1 PS11 <10 <1 >7.1 PS12 <10 <1 >7.1 PS13 <10 <1 >7.1 PS14 <10 <1 >7.1 PS15 <10 <1 >7.1 PS16 <10 <1 >7.1 PS17 <10 <1 >7.1 PS18 <10 <1 >7.1 PS19 <10 <1 >7.1 PS20 <10 <1 >7.1 PS21 <10 <1 >7.1 PS22 <10 <1 >7.1 PS23 <10 <1 >7.1 PS24 <10 <1 >7.1 PS25 <10 <1 >7.1 PS26 <10 <1 >7.1 PS27 <10 <1 >7.1 PS28 <10 <1 >7.1 PS29 <10 <1 >7.1 PS30 <10 <1 >7.1 PS31 <10 <1 >7.1 PS32 <10 <1 >7.1 PS33 <10 <1 >7.1 PS34 <10 <1 >7.1 PS35 <10 <1 >7.1 PS36 <10 <1 >7.1 PS37 <10 <1 >7.1 PS38 <10 <1 >7.1 PS39 <10 <1 >7.1 PS40 <10 <1 >7.1 PS41 <10 <1 >7.1 PS42 <10 <1 >7.1 PS43 <10 <1 >7.1 PS44 <10 <1 >7.1 PS45 <10 <1 >7.1 PS46 <10 <1 >7.1 PS47 <10 <1 >7.1 PS48 <10 <1 >7.1 PS49 410 2.6 5.5 PS50 20 1.3 6.8 PS51 <10 <1 >7.1 PS52 <10 <1 >7.1 PS53 <10 <1 >7.1 PS54 <10 <1 >7.1 PS55 <10 <1 >7.1 PS56 10 1 7.1 PS57 <10 <1 >7.1 PS58 <10 <1 >7.1 PS59 <10 <1 >7.1 PS60 <10 <1 >7.1 PS61 <10 <1 >7.1 PS62 <10 <1 >7.1 PS63 <10 <1 >7.1 PS64 <10 <1 >7.1 PS65 <10 <1 >7.1 PS66 <10 <1 >7.1 PS67 <10 <1 >7.1 PS68 <10 <1 >7.1 PS69 <10 <1 >7.1 PS70 <10 <1 >7.1 - As shown in TABLE 5, water activity of sterilized mixed allergen product after
validation trial 2 dry heat sterilization is similar to the water activity of bulk mixed allergen material before dry heat treatment. Moisture content and total plate counts were lower following dry heat sterilization treatment invalidation trial 2, as compared to bulk mixed allergen material that was not dry heat sterilized. -
TABLE 5 Water Moisture Log Total Plate Activity (aw) Content (%) Count Bulk Mixed Allergen 0.285 ± 0.005 1.95 ± 0.10 % 3.0 ± 0.3 log cfu/g Material (before dry heat sterilization) Mixed Allergen 0.301 ± 0.054 1.22 ± 0.12 % 2.5 ± 0.1 log cfu/g Product (after dry heat sterilization) - As shown in TABLE 6, bulk mixed allergen material samples that were not treated with dry heat sterilization had a mean SurroNov® 1830 count of 8.1±0.1 log cfu/g.
-
TABLE 6 Control Sample CFU/ g Log Mean 1 1.5 × 108 8.2 8.1 ± 0.1 2 1.3 × 108 8.1 3 1.1 × 108 8.0 4 1.1 × 108 8.0 5 6.9 × 107 7.8 6 1.3 × 108 8.1 7 1.1 × 108 8.0 8 1.4 × 108 8.1 - Similarly to dry heat sterilization in
validation trial 1, as shown in TABLE 7, dry heat sterilization invalidation trial 2 resulted in greater than 5 log reductions in SurroNov® 1830 CFU/g in all samples, as compared to inoculated bulk mixed allergen material samples that were not dry heat treated. -
TABLE 7 ID CFU/g Log Log Reduction PS7 <10 <1 >7.1 PS8 <10 <1 >7.1 PS9 <10 <1 >7.1 PS10 <10 <1 >7.1 PS11 <10 <1 >7.1 PS12 <10 <1 >7.1 PS13 <10 <1 >7.1 PS14 <10 <1 >7.1 PS15 <10 <1 >7.1 PS16 <10 <1 >7.1 PS17 <10 <1 >7.1 PS18 <10 <1 >7.1 PS19 <10 <1 >7.1 PS20 <10 <1 >7.1 PS21 <10 <1 >7.1 PS22 <10 <1 >7.1 PS23 <10 <1 >7.1 PS24 <10 <1 >7.1 PS25 <10 <1 >7.1 PS26 20 1.3 6.8 PS27 <10 <1 >7.1 PS28 <10 <1 >7.1 PS29 <10 <1 >7.1 PS30 <10 <1 >7.1 PS31 <10 <1 >7.1 PS32 <10 <1 >7.1 PS33 <10 <1 >7.1 PS34 <10 <1 >7.1 PS35 <10 <1 >7.1 PS36 <10 <1 >7.1 PS37 20 1.3 6.8 PS38 <10 <1 >7.1 PS39 <10 <1 >7.1 PS40 <10 <1 >7.1 PS41 <10 <1 >7.1 PS42 <10 <1 >7.1 PS43 <10 <1 >7.1 PS44 <10 <1 >7.1 PS45 <10 <1 >7.1 PS46 <10 <1 >7.1 PS47 <10 <1 >7.1 PS48 <10 <1 >7.1 PS49 410 2.6 5.5 PS50 20 1.3 6.8 PS51 <10 <1 >7.1 PS52 <10 <1 >7.1 PS53 <10 <1 >7.1 PS54 <10 <1 >7.1 PS55 <10 <1 >7.1 PS56 10 1 7.1 PS57 <10 <1 >7.1 PS58 <10 <1 >7.1 PS59 <10 <1 >7.1 PS60 <10 <1 >7.1 PS61 <10 <1 >7.1 PS62 <10 <1 >7.1 PS63 <10 <1 >7.1 PS64 <10 <1 >7.1 PS65 <10 <1 >7.1 PS66 <10 <1 >7.1 PS67 <10 <1 >7.1 PS68 <10 <1 >7.1 PS69 <10 <1 >7.1 PS70 <10 <1 >7.1 - Particle size distribution can be measured for mixed allergen product samples treated with dry heat sterilization and compared to the particles of corresponding bulk mixed allergen material that did not receive application of dry heat sterilization. Samples can be filtered for 3 minutes using a Ro-Tap® sieve shaker and a series of mesh sizes consisting of #10, #12, #14, #16, #18, #20, #25, #30, #35, #40, and #50 meshes. Filtered particles and particles retained by each mesh can be individually removed, weighed, and distributions plotted as % weight versus particle size (in m).
- Protein integrity of mixed allergen product samples treated with dry heat sterilization can be compared to bulk mixed allergen material that did not receive application of dry heat sterilization. Protein integrity can be assessed by resolving all proteins present in non-sterilized and dry heat-sterilized samples by SDS-PAGE.
- 1 mg of bulk mixed allergen material or dry heat sterilized mixed allergen product can be weighed into 2 mL microtubes. Based on their assessed protein concentrations, samples can be diluted with Laemmli buffer containing 5% 2-mercaptoethanol (BioRad, Hercules, California) to a protein concentration of 1 mg/ml. Protein suspensions can be mixed by gentle inversion or intermittent vortexing for 5 minutes then heated to 95° C. to 100° C. for 5 minutes. Samples can be centrifuged for 1 minute at 1,000 RPM, then 10 μl of each sample can be loaded per well, in triplicate, on a 4-20% polyacrylamide gradient gel (BioRad, Hercules, California) immersed in 1×SDS-PAGE running buffer (BioRad, Hercules, California). Gels can be run at 100 V for 80-90 minutes (or 200V for 30-40 minutes). Gels can then be washed 3 times with distilled water, 5 minutes per wash, on an orbital shaker at room temperature. Gels can be fixed in fixing solution (Sigma-Aldrich, St. Louis, Missouri) or 50% methanol, 10% acetic acid, for 15 minutes. Gels can be stained with EX Blue gel staining reagent (Sigma-Aldrich, St. Louis, Missouri) for 2 hours or overnight, then de-stained by washing in distilled water for 1-2 hours or overnight. Upon completion of washing, gels can be covered with clear plastic and scanned using a gel reader. Protein band densitometry can be analyzed using ImageJ public domain software (NIH, Bethesda, Maryland).
- The visual and organoleptic characteristics of mixed allergen product samples treated with dry heat sterilization can be compared to bulk mixed allergen material that did not receive application of dry heat sterilization. A comparison of taste profiles of dry heat sterilized mixed allergen product and non-sterilized bulk mixed allergen can also be performed.
- All publications and patents mentioned herein are hereby incorporated by reference in their entirety for all purposes. In case of conflict, the present application, including any definitions herein, will control.
- While specific embodiments of the subject invention have been discussed, the above specification is illustrative and not restrictive. Many variations of the invention will become apparent to those skilled in the art upon review of this specification. The full scope of the invention should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations.
- Unless otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in this specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention.
Claims (26)
1. A method of making a mixed allergen product substantially free of replication viable organisms, comprising:
providing bulk mixed allergen material comprising 2 to 20 individual complete food allergens; and
sterilizing the bulk mixed allergen material by dry heat sterilization, thereby obtaining the mixed allergen product.
2. The method of claim 1 , further comprising providing 2 to 20 individual complete food allergens, and blending the 2 to 20 individual complete food allergens together to obtain the bulk mixed allergen material,
wherein:
the individual complete food allergens are selected from the group consisting of almond, cashew, cod, egg, hazelnut, milk, oat, peanut, pecan, pistachio, salmon, sesame, shrimp, soy, walnut, and wheat; and/or
blending further comprises blending the 2 to 20 individual complete food allergens with one or more than one bulking agent; and/or
after blending, the bulk mixed allergen material is discharged into lined drums.
3-6. (canceled)
7. The method of claim 1 , wherein the dry heat sterilization is at a temperature of about 65° C. to about 175° C. for about 18 hours to about 72 hours,
wherein:
the dry heat sterilization comprises using a sterilization system having a furnace and a heating chamber, wherein the furnace provides about 250,000 BTUs to about 750,000 BTUs of heat to the heating chamber; and/or
the bulk mixed allergen material is first packaged into thermoresistant packaging before sterilizing; and/or
temperature probes are placed with the bulk mixed allergen material during sterilizing to monitor the temperature of the dry heat sterilization.
8-10. (canceled)
11. The method of claim 1 , wherein the mixed allergen product has at least about a 1 log reduction to at least about a 4 log reduction in aerobic bacterial organism plate counts as compared to corresponding bulk mixed allergen material that has not been sterilized.
12. The method of claim 1 , wherein the mixed allergen product has:
less than about 100,000 CFU/g of aerobic bacterial organisms, and/or
less than about 10 CFU/g of coliforms, and/or
less than about 10 CFU/g of Escherichia coli, and/or
less than about 10 CFU/g of Enterobacteriaceae, and/or
less than about 10 CFU/g of Salmonella, and/or
less than about 10 CFU/g of Cronobacter, and/or
less than about 10 CFU/g of Staphylococcus aureus, and/or
less than about 10 CFU/g of yeast, and/or
less than about 10 CFU/g of mold.
13-17. (canceled)
18. The method of claim 1 , wherein the mixed allergen product is negative in a PCR-based assay for Listeria species or Cronobacter species per 25 grams of the mixed allergen product.
19. (canceled)
20. The method of claim 1 , wherein the mixed allergen product is negative in a PCR-based assay for Salmonella species per 375 g of the mixed allergen product.
21. (canceled)
22. (canceled)
23. The method of claim 1 , wherein the mixed allergen product has a fat content of about 10% to about 20% by weight.
24. The method of claim 1 , wherein protein integrity of the mixed allergen product is substantially similar to protein integrity of corresponding bulk mixed allergen material that has not been sterilized.
25. The method of claim 24 , wherein the protein integrity of the mixed allergen product is determined by SDS-PAGE.
26. The method of claim 1 , wherein the mixed allergen product has a protein content of about 40% to about 50% by weight.
27. The method of claim 1 , wherein the mixed allergen product has about 1% to about 10% moisture by weight.
28. The method of claim 1 , wherein the mixed allergen product has a water activity of about 0.1 to about 0.6.
29. The method of claim 1 , wherein less than about 10% by weight of the mixed allergen product are particles having a diameter greater than 500 μm.
30. The method of claim 1 , wherein the mixed allergen product is darker in color as compared to corresponding bulk mixed allergen material that has not been sterilized.
31. The method of claim 1 , wherein the mixed allergen product has a substantially similar taste profile as compared to corresponding bulk mixed allergen material that has not been sterilized.
32. The method of claim 1 , wherein sterilizing further comprises one or more than one further application of dry heat sterilization.
33. A method of making a mixed allergen product substantially free of replication viable organisms, comprising:
providing 2 to 20 individual complete food allergens;
sterilizing each of the 2 to 20 individual complete food allergens by dry heat sterilization, thereby obtaining 2 to 20 sterilized individual complete food allergens; and
blending the 2 to 20 sterilized individual complete food allergens together, thereby obtaining the mixed allergen product.
34-40. (canceled)
41. A mixed allergen product substantially free of replication viable organisms prepared by the method of claim 1 .
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/232,547 US20230390387A1 (en) | 2019-01-23 | 2023-08-10 | Methods for making mixed allergen compositions |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962795877P | 2019-01-23 | 2019-01-23 | |
US201962865473P | 2019-06-24 | 2019-06-24 | |
US16/750,522 US11766477B2 (en) | 2019-01-23 | 2020-01-23 | Methods for making mixed allergen compositions |
US18/232,547 US20230390387A1 (en) | 2019-01-23 | 2023-08-10 | Methods for making mixed allergen compositions |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/750,522 Continuation US11766477B2 (en) | 2019-01-23 | 2020-01-23 | Methods for making mixed allergen compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230390387A1 true US20230390387A1 (en) | 2023-12-07 |
Family
ID=69726758
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/750,522 Active 2041-07-08 US11766477B2 (en) | 2019-01-23 | 2020-01-23 | Methods for making mixed allergen compositions |
US18/232,547 Pending US20230390387A1 (en) | 2019-01-23 | 2023-08-10 | Methods for making mixed allergen compositions |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/750,522 Active 2041-07-08 US11766477B2 (en) | 2019-01-23 | 2020-01-23 | Methods for making mixed allergen compositions |
Country Status (12)
Country | Link |
---|---|
US (2) | US11766477B2 (en) |
EP (1) | EP3914098A1 (en) |
JP (1) | JP2022519817A (en) |
KR (1) | KR20210130147A (en) |
CN (1) | CN113507844A (en) |
AU (1) | AU2020213085A1 (en) |
BR (1) | BR112021014486A2 (en) |
CA (1) | CA3127337A1 (en) |
IL (1) | IL284997A (en) |
MX (1) | MX2021008873A (en) |
SG (1) | SG11202108043PA (en) |
WO (1) | WO2020154476A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3127337A1 (en) | 2019-01-23 | 2020-07-30 | Before Brands, Inc. | Methods for making mixed allergen compositions |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3627543A (en) | 1969-02-18 | 1971-12-14 | Jacob J Epstein | Pan dried glucose free egg white albumen containing means for inhibiting discoloration when heat treated and the process of preparing the same |
US4031199A (en) | 1972-12-11 | 1977-06-21 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Process for the production of allergen-containing extracts |
GB8403675D0 (en) | 1984-02-13 | 1984-03-14 | Griffith Laboratories | Food coating compositions |
GB9323483D0 (en) | 1993-11-13 | 1994-01-05 | Cerestar Holding Bv | Edible composition and a process for its preparation |
US20020018778A1 (en) | 1999-12-06 | 2002-02-14 | Caplan Michael J. | Passive desensitization |
AU2001263073A1 (en) | 2000-05-12 | 2001-11-26 | Sigmund Kramer | Peanut powder compositions and methods of making same |
FR2822709B1 (en) | 2001-03-30 | 2007-01-19 | Antialis | ANTI-ALLERGIC PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE ALLERGEN AND AT LEAST ONE ANTIHISTAMINE COMPOUND |
US6852957B2 (en) | 2002-06-28 | 2005-02-08 | Kerry Group Services International, Ltd. | Breadcrumb processing line and method |
DK1641488T3 (en) | 2003-06-23 | 2011-07-18 | Biotech Tools Sa | Epitope Composition for Enteric Administration Prepared by Hydrolysis of Antigen Structures with Chymotrypsin |
US20050025862A1 (en) | 2003-07-29 | 2005-02-03 | Schwan's Food Manufacturing, Inc. | Multi-component dough |
US7595081B1 (en) | 2003-10-17 | 2009-09-29 | Bellar Willis F | Non-flour containing baked and related food compositions |
US8491909B2 (en) | 2004-02-06 | 2013-07-23 | Greer Laboratories, Inc. | Methods and compositions for dosing of allergens |
WO2007096838A1 (en) | 2006-02-27 | 2007-08-30 | The Iams Company | Animal food composition comprising nut shell |
EP1872792A1 (en) | 2006-06-29 | 2008-01-02 | Biotech Tools S.A. | A method for the production of hydrolyzed allergen |
GB0616494D0 (en) | 2006-08-18 | 2006-09-27 | Council Cent Lab Res Councils | Armour |
EP2077821B1 (en) | 2006-10-12 | 2019-08-14 | The University Of Queensland | Compositions and methods for modulating immune responses |
CN101646418B (en) | 2006-10-12 | 2013-07-17 | 昆士兰大学 | Compositions and methods for modulating immune responses |
US8709413B2 (en) | 2006-12-13 | 2014-04-29 | Michael R. Simon | Treatment of celiac disease with IgA |
MX2010001779A (en) | 2007-08-15 | 2010-07-06 | Circassia Ltd | Peptides for desensibilization against allergens. |
FR2924349B1 (en) | 2007-12-03 | 2010-01-01 | Dbv Tech | ALLERGEN DISENSIBILITY METHOD |
WO2009083589A1 (en) | 2008-01-02 | 2009-07-09 | Biotech Tools S.A. | Pharmaceutical formulation for allergen preparation |
WO2009154588A2 (en) | 2008-01-14 | 2009-12-23 | General Mills, Inc. | Microwave batter product |
ES2585407T3 (en) | 2008-02-01 | 2016-10-05 | Murdoch Childrens Research Institute | A method to induce tolerance to an allergen |
EP2140880B1 (en) | 2008-07-04 | 2012-11-14 | HAL Allergy Holding B.V. | Modification of allergens |
WO2010009417A1 (en) | 2008-07-17 | 2010-01-21 | John Shea | Method for testing and treating delayed food allergies |
JP5805363B2 (en) | 2009-06-26 | 2015-11-04 | 和興フィルタテクノロジー株式会社 | Soluble aggregate, immune tolerance inducer and method for producing the same |
PT2467031E (en) | 2009-08-18 | 2014-10-30 | Nestec Sa | A nutritional composition comprising lactococcus strains and reducing allergy symptoms, especially in infants and children. |
BR112012005117A2 (en) | 2009-09-07 | 2016-05-03 | Dbv Tech | eosinophilic esophagitis treatment method |
CN102048077A (en) | 2009-10-30 | 2011-05-11 | 梁振 | Convenient and nutritious pudding beancurd jelly |
EP2563390A4 (en) * | 2010-04-30 | 2014-05-14 | Allovate Llc | Methods and articles for preventing or reducing risk of developing a hyperallergenic immune system |
TR201906326T4 (en) | 2010-04-30 | 2019-05-21 | Allovate Llc | Toothpaste for allergic desensitization with oral mucosa. |
GB201009368D0 (en) | 2010-06-04 | 2010-07-21 | Sana Pharma As | Dietary formulations |
EA201390559A1 (en) | 2010-10-15 | 2013-08-30 | Альк-Абелло А/С | SUPPRESSION OF IMMUNE RESPONSE BY THE TYPE OF HYPERSENSITIVITY BY NON-DOMINAL ANTIGEN, RECEIVED FROM THE MATERIAL OF SOURCE ALLERGENS |
GB201104537D0 (en) | 2011-03-17 | 2011-05-04 | Cambridge Entpr Ltd | Treatment for peanut allergy |
WO2013078510A1 (en) | 2011-12-02 | 2013-06-06 | Climax Holdings Pty Limited | Milk analogues produced from nuts |
WO2013087119A1 (en) | 2011-12-16 | 2013-06-20 | Hal Allergy Holding B.V. | Pharmaceutical formulations and the use thereof for the treatment of peanut allergy |
CN104185428A (en) * | 2011-12-29 | 2014-12-03 | 雅培制药有限公司 | Methods for reducing microbial contamination of dryblended powdered nutritional compositions |
EP2626082A1 (en) | 2012-02-13 | 2013-08-14 | DBV Technologies | Method of preventing allergies |
EP2833911A4 (en) | 2012-04-06 | 2016-07-13 | Univ Cornell | Subunit vaccine delivery platform for robust humoral and cellular immune responses |
EP2861240B1 (en) | 2012-06-15 | 2020-09-09 | Immunomic Therapeutics, Inc. | Nucleic acids for treatment of allergies |
US20140023757A1 (en) | 2012-07-17 | 2014-01-23 | Honeyville Grain, Inc. | Thermal processes of reducing foodborne pathogens in bagged food products |
EP2689833A3 (en) | 2012-07-27 | 2015-05-13 | Marion Mixers, Inc. | Mixing apparatus |
CN102986802A (en) | 2012-12-11 | 2013-03-27 | 崔杰 | Making method of salted peanut and walnut cake |
PT2968529T (en) | 2013-03-14 | 2020-11-10 | Aimmune Therapeutics Inc | Manufacture of peanut formulations for oral desensitization |
WO2014159609A1 (en) | 2013-03-14 | 2014-10-02 | Allergen Research Corporation | Peanut formulations and uses thereof |
US20160030553A1 (en) | 2013-03-19 | 2016-02-04 | Biotech Tools S.A. | Allergen preparation |
CA2914037A1 (en) | 2013-06-06 | 2014-12-11 | Anergis S.A. | Contiguous overlapping peptides for treatment of house dust mites allergy |
WO2015042402A1 (en) | 2013-09-19 | 2015-03-26 | Allovate, Llc | Toothpaste for delivering allergens to oral mucosa |
ITVR20130220A1 (en) | 2013-09-27 | 2015-03-28 | Stalam S P A | EQUIPMENT AND METHOD FOR THE DRYING AND / OR TREATMENT OF BREWED FOOD PRODUCTS. |
BR112016016525A2 (en) | 2014-01-17 | 2017-08-08 | Dbv Tech | METHOD FOR INDUCING TREG (CTLA-4+, CD4+, CD25+) FOXP3+ AND/OR TREG LAP+ CELLS IN AN INDIVIDUAL, METHOD FOR IMPROVING A CONDITION IN AN INDIVIDUAL, AND METHOD FOR PRODUCING TREG (CTLA-4+, CD4+, CD25+) FOXP3+ AND/OR TREG LAP+ CELLS |
ES2768716T3 (en) | 2014-04-10 | 2020-06-23 | Asit Biotech S A | HSP-free allergen preparation |
US20150343075A1 (en) | 2014-06-02 | 2015-12-03 | Aimmune Therapeutics | Placebo formulations and uses thereof |
EP2952200A1 (en) | 2014-06-04 | 2015-12-09 | Alk-Abelló A/S | Allergen for prophylactic treatment of allergy |
US20170304432A1 (en) | 2014-06-23 | 2017-10-26 | Immunomic Therapeutics, Inc. | Nucleic acids for treatment of peanut allergies |
MX2017001682A (en) | 2014-08-04 | 2017-04-27 | Dbv Tech | Compositions of food allergens. |
US20160051639A1 (en) | 2014-08-25 | 2016-02-25 | Aimmune Therapeutics, Inc. | Egg protein formulations and methods of manufacture thereof |
CN104273238A (en) | 2014-09-27 | 2015-01-14 | 合肥市凤落河豆制食品有限公司 | Sesame sauced dried bean curd and preparation method thereof |
CA2962791C (en) | 2014-11-07 | 2023-08-22 | North Carolina State University | Methods and compositions for attenuating allergenicity in protein products |
US10166286B2 (en) | 2015-02-20 | 2019-01-01 | The Board Of Trustees Of The Leland Stanford Junior University | Mixed allergen compositions and methods for using the same |
PT3258962T (en) | 2015-02-20 | 2023-02-16 | Univ Leland Stanford Junior | Mixed allergen compositions and methods for using the same |
US11452774B2 (en) | 2015-02-20 | 2022-09-27 | The Board Of Trustees Of The Leland Stanford Junior University | Mixed allergen compositions and methods for using the same |
US10149904B2 (en) | 2015-02-20 | 2018-12-11 | The Board Of Trusteees Of The Leland Stanford Junior University | Mixed allergen compositions and methods for using the same |
US10143742B2 (en) | 2015-02-20 | 2018-12-04 | The Board Of Trustees Of The Leland Stanford Junior University | Mixed allergen compositions and methods for using the same |
US20160263212A1 (en) | 2015-02-23 | 2016-09-15 | Antera Therapeutics Inc. | Compositions and methods for tolerizing the immune system to allergens |
US10244777B2 (en) | 2015-05-16 | 2019-04-02 | Big Heart Pet, Inc. | Palatable expanded food products and methods of manufacture thereof |
GB201509718D0 (en) | 2015-06-04 | 2015-07-22 | Reacta Biotech Ltd | Oral food challenge meal formulations |
US20190046444A1 (en) | 2015-09-14 | 2019-02-14 | Vgsk Techologies, Inc. | A sterically stabilized carrier for subcutaneous, sublingual, and oral therapeutics, compositions and methods for treating a mammal |
WO2017139558A1 (en) | 2016-02-12 | 2017-08-17 | Virtici, Llc | Tolerance therapeutic for treating polypeptide induced immune activation |
US20170360922A1 (en) | 2016-06-21 | 2017-12-21 | Paul Turke | Nutritional supplements and methods for primary prevention of food allergies |
US10856567B2 (en) | 2016-07-22 | 2020-12-08 | Kari Brown | Baby food products containing allergenic proteins and methods of delivering same |
CN109890414A (en) | 2016-10-05 | 2019-06-14 | Asit生物技术公司 | It is pre- hypo-allergenic |
EP3541420A2 (en) | 2016-11-16 | 2019-09-25 | Immunomic Therapeutics, Inc. | Nucleic acids for treatment of allergies |
CN110114062B (en) | 2016-11-21 | 2023-04-07 | 雀巢产品有限公司 | Liquid allergen compositions and methods of making the same |
WO2018112553A1 (en) | 2016-12-23 | 2018-06-28 | Murdoch Childrens Research Institute | Methods and compositions for determining, and for minimizing, the likelihood of development of allergy in infants |
SG11201906301UA (en) | 2017-01-13 | 2019-08-27 | Aimmune Therapeutics Inc | Methods of manufacture of nut flours and formulations for oral immunotherapy |
IL272033B2 (en) | 2017-07-18 | 2023-09-01 | Before Brands Inc | Methods for making mixed allergen compositions |
BR112021010435A2 (en) | 2018-11-30 | 2021-08-24 | Alladapt Immunotherapeutics, Inc. | Methods for making mixed allergen compositions |
CA3127337A1 (en) | 2019-01-23 | 2020-07-30 | Before Brands, Inc. | Methods for making mixed allergen compositions |
-
2020
- 2020-01-23 CA CA3127337A patent/CA3127337A1/en active Pending
- 2020-01-23 MX MX2021008873A patent/MX2021008873A/en unknown
- 2020-01-23 KR KR1020217026140A patent/KR20210130147A/en unknown
- 2020-01-23 AU AU2020213085A patent/AU2020213085A1/en active Pending
- 2020-01-23 SG SG11202108043PA patent/SG11202108043PA/en unknown
- 2020-01-23 EP EP20708306.4A patent/EP3914098A1/en active Pending
- 2020-01-23 JP JP2021542430A patent/JP2022519817A/en active Pending
- 2020-01-23 BR BR112021014486-2A patent/BR112021014486A2/en unknown
- 2020-01-23 US US16/750,522 patent/US11766477B2/en active Active
- 2020-01-23 CN CN202080017162.XA patent/CN113507844A/en active Pending
- 2020-01-23 WO PCT/US2020/014748 patent/WO2020154476A1/en unknown
-
2021
- 2021-07-20 IL IL284997A patent/IL284997A/en unknown
-
2023
- 2023-08-10 US US18/232,547 patent/US20230390387A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20210130147A (en) | 2021-10-29 |
CN113507844A (en) | 2021-10-15 |
US20200230232A1 (en) | 2020-07-23 |
JP2022519817A (en) | 2022-03-25 |
CA3127337A1 (en) | 2020-07-30 |
MX2021008873A (en) | 2021-11-04 |
AU2020213085A1 (en) | 2021-08-12 |
EP3914098A1 (en) | 2021-12-01 |
SG11202108043PA (en) | 2021-08-30 |
IL284997A (en) | 2021-09-30 |
WO2020154476A1 (en) | 2020-07-30 |
BR112021014486A2 (en) | 2021-09-28 |
US11766477B2 (en) | 2023-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Schmitz et al. | Understanding the canine intestinal microbiota and its modification by pro‐, pre‐and synbiotics–what is the evidence? | |
RU2549934C2 (en) | Baby porridges containing non-replicating probiotic microorganisms | |
Deshpande et al. | Evidence-based guidelines for use of probiotics in preterm neonates | |
EP2033529B1 (en) | Synbiotic composition for infants | |
CA2625074C (en) | Use of lactobacillus for treatment of virus infections | |
JP4974881B2 (en) | Immune function regulator | |
Kneifel et al. | Probiotics and health claims | |
Wang et al. | Intestinal microbiota profiles of healthy pre-school and school-age children and effects of probiotic supplementation | |
US20170157185A1 (en) | Probiotic derived non-viable material for infection prevention and treatment | |
US20230390387A1 (en) | Methods for making mixed allergen compositions | |
CN111935995A (en) | Nutritional composition, and food and drink composition and formulated milk powder using the same | |
AU2017251028A1 (en) | Brain function-improving composition for newborns | |
KR20170105011A (en) | Immunomodulatory composition comprising bifidobacteria | |
Thantsha et al. | Probiotics–what they are, their benefits and challenges | |
TW201722447A (en) | Infection preventive agent for infants | |
Dominici et al. | In vivo antigenotoxic properties of a commercial probiotic supplement containing bifidobacteria | |
WO2017069167A1 (en) | Antiallergic agent for infants | |
Leghari et al. | Beneficial aspects of probiotics, strain selection criteria and microencapsulation using natural biopolymers to enhance gastric survival: A review | |
Speranza et al. | The impact of gluten friendly flour on the functionality of an active drink: viability of Lactobacillus acidophilus in a fermented milk | |
Afraei et al. | Improvement the texture of nitrite-free fermented sausages using microencapsulation of fermenting bacteria | |
Fatemeh et al. | Optimization of a cryoprotective medium and survival of freeze-dried Bifidobacterium infantis 20088 throughout storage, rehydration and gastrointestinal tract transit for infant formula probiotic applications | |
Chowdhury et al. | Isolation and Characterization of Probiotic Strain from Traditional Fermented Food | |
Saxelin et al. | Developing a multispecies probiotic combination. | |
CN112543641A (en) | Composition for inhibiting expression of fcsri and method for inhibiting expression of fcsri | |
Lahtinen et al. | Developing effective probiotic products: Bioavailability and other factors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |